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Abstract
The diverse applications of MALDI MSI are explored in this thesis with an emphasis 
on the sample preparation procedure and method development for small molecule 
analysis for a range of samples. The two main themes that have been focussed on are 
the pharmaceutical and metabolomic applications of this state of the art technique.
MALDI MSI has been evaluated as a technique for the detection and imaging of anti­
asthmatic compounds in lung tissue. Four compounds were assessed initially with 
conventional MALDI MS experiments, followed by both direct and indirect tissue 
imaging experiments.
Pharmaceutical tablet formulations have also been assessed using MALDI MSI to 
map the active component throughout the excipients contained within the tablet 
providing information that is critical to the manufacturing process such as the 
homogeneity of the active pharmaceutical ingredient (API) throughout the tablet.
MALDI MSI has been applied to the relatively new addition to the 'omics sciences, 
metabolomics. A non-targeted metabolomics approach has been used to study both 
plant and animal tissue in an attempt to gain a greater understanding of the complex 
biological processes that occur within both types of tissue.
Wheat grain was used as the model system to conduct the experiments and evaluate 
the application of both UV MALDI MS and IR LDI MS for plant metabolomics. 
These techniques provided complementary information to published literature, 
however the novel aspect of this study was the incorporation of imaging experiments 
for UV MALDI MS; this allowed the metabolites to be visualised in the wheat grain 
section.
MALDI MSI was also used to explore the differences between mice with chronic 
relapsing experimental autoimmune encephalomyelitis; the animal model of multiple 
sclerosis alongside healthy controls. Spinal cord samples were analysed and the 
main difference was tentatively attributed to choline levels.
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Introduction
1.1 Introduction to Mass Spectrometry
Mass spectrometry is an analytical technique that is used to measure the masses of 
individual molecules or atoms by the determination of the mass to charge ratio (m/z). 
There are three fundamental parts to a mass spectrometer: the ionisation source; the 
analyser and the detector. Initially the sample is introduced into the ionisation source 
either directly or indirectly. The ions formed are then subjected to electrostatic and / 
or magnetic fields that direct the ions into the mass analyser where they are separated 
according to their m/z values [1]. The detector converts ion energy into electrical 
signals; these signals are subsequently transmitted to a computer and information 
regarding m/z values and their corresponding relative abundances are collected and 
presented in the form of a mass spectrum. The mass spectrometer operates under 
high vacuum of ~ 10'4 -  10‘8 Torr to enable the ions to travel without interference 
from air molecules [2]. In recent years, technological improvements have made it 
possible to analyse a multitude of diverse samples and it is for this reason that mass 
spectrometry is such an invaluable technique in the biomedical sciences. Mass 
spectrometry has a prominence in many areas of science; the scope of which 
encompasses physics, biology, chemistry, material science and environmental 
sciences. The hallmarks of mass spectrometry include excellent sensitivity, 
molecular specificity and versatility.
1.2 Ionisation Sources
There are many methods of ionisation available to produce ions in the gas phase: 
electron ionisation (El) [3]; chemical ionisation (Cl) [4]; fast atom/ion bombardment 
(FAB) [5]; secondary ion mass spectrometry (SIMS) [6]; electrospray ionisation (ESI) 
[7]; nanoelectrospray ionisation (nanoESI) [8]; atmospheric pressure chemical 
ionisation (APCI) t9]; desorption/ionisation on silicon (DIOS) I10]; desorption 
electrospray ionisation (DESI) [11] and matrix-assisted laser desorption/ionisation 
(MALDI)[I2>13].
In the past, mass spectrometry was primarily carried out using El as the ionisation 
source; however, a major limitation was that researchers were only able to detect
small molecules [14]. This encouraged researchers to develop alternative ionisation 
sources (examples include FAB, MALDI and ESI) that could enable them to study a 
range of biomolecules. The advent of ESI and MALDI ionisation techniques have 
permitted the analysis of biomolecules with unprecedented accuracy and speed; 
leading to this type of mass spectrometry being an integral part of biochemistry and 
medicine. MALDI and ESI are now the ionisation sources of choice for the majority 
of biomedical applications.
1.2.3 Spray Ionisation Techniques
Spray techniques were introduced to enable the direct sampling of solutions such as 
biological fluids and eluents from chromatographic techniques coupled to the mass 
spectrometer as liquids are not suited to the vacuum in the mass spectrometer.
1.2.3.1 Atmospheric Pressure Chemical Ionisation (APCI)
APCI can be used for the analysis of non-volatile samples without the requirement to 
first convert them to a gaseous state; analysis of liquids is achieved by the spraying 
of the samples directly into the ion source. The ionisation is similar to Cl whereby 
gas-phase ion-molecule charge transfer reactions take place with the reagent gas ions 
and the analyte molecules [9]. The analyte solution is vaporised using heat and 
desolvated before interacting with the corona discharge; this results in ion formation 
[15]. At atmospheric pressure ions can be involved in more ion-molecule collisions, 
and therefore APCI is a more sensitive technique than that of CL
1.2.3.2 Electrospray Ionisation (ESI)
ESI, a concept introduced in the late 1960’s by Dole et a l  [7], is an atmospheric 
ionisation technique that can be used for the analysis of biomolecules and is often the 
ionisation interface used in conjunction with liquid chromatography. In the mid- 
1980's ESI was coupled to mass spectrometry by Fenn et a l  [16]; this was applied to
the analysis of biomolecules in 1989 [,7]. The liquid sample is injected into a 
capillary and on exiting the capillary a fine mist of charged droplets is produced 
brought about by the potential difference between the capillary tip and the 
surrounding atmospheric pressure area. Nitrogen gas is present near the ESI 
interface to facilitate the evaporation of solvent from the charged droplets. Prior to 
mass analysis the ions enter a region under high vacuum and are desolvated.
1.2.4 Desorption Ionisation Techniques
Desorption ionisation techniques were introduced due to the limitations with both 
electron ionisation and chemical ionisation as these types of ionisation are not 
suitable for compounds that are thermally labile. Biological samples contain a 
diverse array of compounds that are often thermally labile and non volatile. Thus the 
introduction of desorption ionisation techniques has allowed for the analysis of many 
more biomolecules beyond the 100,000Da mass range [l2].
1.2.4.1 Secondary Ion Mass Spectrometry (SIMS)
SIMS is a surface analysis technique where the sample surface is irradiated with a 
high energy primary ion beam such as liquid metal ions (LMI), for example Ga+ or 
In+ [18, 19]. This results in the ejection of atomic secondary ions and molecular 
fragments from the sample surface. The secondary ions are then mass analysed. 
Good lateral resolution can be achieved using this technique. The introduction of 
cluster ion beams and time-of-flight (TOF)-MS analysers has widened the scope for 
SIMS applications [20].
to Mass Spectrometer
Beam of Secondary Ions 
to Be Analysed
Ions
Sample
Figure 1.1: Schematic Diagram of the SIMS Ionisation Process. The primary ion 
beam irradiates the sample surface resulting in the formation of atomic secondary 
ions and molecular fragments being ejected from the surface of the sample. Adapted 
from [2I].
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1.2.4.2 Fast Atom/Ion Bombardment (FAB)
Developed and pioneered by Barber and co-workers in the 1980’s [5] FAB originated 
from SIMS [6]. FAB differs from SIMS in three ways; first, samples to be analysed 
are dissolved in a matrix, for example glycerol, in order to prolong the sample 
current duration, secondly, a beam of high energy atoms is used instead of ions -  this 
change enabled FAB to be used with magnetic sector mass spectrometers, and, 
thirdly, it is considered to be a softer ionisation technique than SIMS. It has been 
likened to MALDI as it incorporates a matrix and produces intact protonated and 
deprotonated molecules |221.
A FAB gun utilises inert gas atoms (Ar or Xe) to generate the fast beam of atoms 
used to bombard the sample; the ions produced are then extracted, accelerated and 
mass analysed f23,24].
1.2.4.3 Desorption/Ionisation On Silicon (DIOS)
Suizdak et al. introduced DIOS [10] in an attempt to avoid interfering matrix 
background signals that are apparent in MALDI analysis. This technique replaces 
the conventional mixing of the matrix and sample; instead samples are placed 
directly onto a modified porous silicon surface and are then bombarded with a laser 
beam [25]. This method of desorption has been used for the analysis of carbohydrates 
[26], peptides [27, 281 and small drug molecules [29]. The presence of high 
concentrations of salts is not detrimental to analysis.
1.2.4.4 Desorption Electrospray Ionisation (DESI)
Pioneered by Cooks and co-workers [11], DESI is a relatively new ionisation 
technique whereby samples can be investigated rapidly (within seconds) in their 
native environment requiring minimal sample preparation. The DESI process 
involves charged droplets generated by electrospray ionisation being directed onto 
the sample surface, where on impact with the sample surface results in the ejection of
charged particles that can be measured by the mass spectrometer producing mass 
spectra similar in appearance to those generated by ESI [1I]. DESI has been used to 
investigate a variety of pharmaceutical samples such as tablets [30,31,321 and illicit 
tablets [33], and plant m aterial[34].
HV power supply
Solvent
Gas capillary Inlet of mass spectrometer
Sample
DesorbedSolvent
capillary
Spray droplets
Freely moving — —  . ....fr
sample stage
Figure 1.2: Schematic Diagram of the DESI Instrumentation. The charged 
droplets from the DESI emitter are directed onto the sample surface; the resulting 
impact causes the ejection of charged particles that are extracted via the sampling 
capillary [35J.
1.2.4.5 Matrix-Assisted Laser Desorption Ionisation (MALDI)
Matrix-Assisted Laser Desorption Ionisation Mass Spectrometry, a soft ionisation 
technique, was developed in the late 1980’s through the work conducted by Tanaka 
[n] and Hillenkamp [13]. This method of ionisation improved on former laser mass 
spectrometry techniques by incorporating a laser-absorbing matrix to minimise 
fragmentation that was observed with laser desorption ionisation mass spectrometry 
(LDI MS) [36]. The use of a chemical matrix facilitates the energy transfer between 
the matrix and the analyte. Despite the extensive use and acceptance of MALDI 
within the scientific community, the underlying ionisation mechanisms are still not 
well understood and many different theories have been put forward; however, it is 
sufficient to say that no one mechanism can explain all the ions formed in a MALDI 
experiment[37]. The proposed mechanisms are discussed in section 1.3.
The first stage in MALDI MS is to select a matrix to enable analysis to be performed 
on the compound of interest. A matrix usually consists of small organic molecules in 
a solvent solution and its role is to absorb energy at the laser wavelength. The matrix 
can be applied to the analyte in many different ways and analysis can be performed 
once the matrix has co-crystallised with the analyte, resulting in a solid deposit of 
analyte molecules embedded in the matrix.
During MALDI analysis the laser fires at the sample and irradiates the crystals 
causing rapid heating of the crystals to occur which leads to localised sublimation. 
This results in a plume of gaseous phase matrix containing the intact analyte and it is 
during this process that ionisation occurs. The three most important processes for ion 
formation to occur are: the close contact of the matrix and analyte molecules; analyte 
desorption from the sample surface; and, finally, efficient ionisation [38].
IncidentLaserB eam
D esorb ed  Proto naled Analyte 
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Co-crystallisation of Matrix with Analyte 
MALDITargetPlate
Figure 1.3: Schematic Diagram of the MALDI Process in Positive Ion Mode.
The laser irradiation of the sample results in the desorption of molecules, generating 
the gas plume where it is thought ionisation occurs.
1.3 Ion Formation Mechanisms in UV-MALDI
The ion formation mechanisms associated with ultra violet (UV)-MALDI have been 
investigated and some of the theories may also apply to infra red (IR)-MALDI.
The underlying mechanisms require further investigation in order to develop more 
standardised methodologies that take into account all the variables that affect the 
results obtained in relation to sensitivity and reproducibility [39].
The main variables are as follows:
■ Matrix selection
■ Physical and chemical analyte characteristics
■ Concentrations of both the matrix and the analyte
■ Sample preparation methodology
■ Features associated with the laser
■ Local environment, for example temperature
There are many different theories regarding the reactions that occur in ion formation 
in the MALDI process. There is an increasing consensus amongst researchers that a 
two-step model exists, where there is a primary ionisation event followed by 
extensive secondary reactions in the plume.
The foremost primary ionisation steps include cluster reactions with preformed ions 
and pooling mediated photoionisation of the matrix. Although the exact reaction 
mechanisms associated with MALDI are not yet fully understood, there have been 
many proposed theories [39]. The importance of secondary reactions is highlighted by 
the fact that many molecules present themselves in spectra in their protonated form
[40, 41]
1.3.1 Primary Ion Formation
1.3.1.1 The Cluster M odel
Introduced by Karas et al.[42\  this model assumes that large protonated analyte 
clusters are preformed in the chemical matrix [43].
The concept behind the cluster model is that post-irradiation of the sample by the 
laser, the clusters are desorbed and in the gas phase neutral matrix molecules are 
desolvated and analyte ions are created.
1.3.1.2 M ultiphoton Ionisation
This is the simplest explanation for ion formation brought about by the transfer of 
energy from the matrix to the sample; it can be represented by the following equation 
whereby a matrix cation radical is formed [36]:
n(hv)
M ---------- ► M+ + e'
M = Matrix Molecule 
M+ =Radical cation 
e~ = electron
h = Planck’s constant (the proportionality constant between the photon energy (E) 
and the frequency of the corresponding radiation frequency) 
v = radiation frequency (electromagnetic wave)
1.3.1.3 G as-phase Proton Transfer
Reactions between matrix molecules do occur in the plume; the formation of reaction 
intermediates may be a fundamental requirement for the protonation of analytes 1401.
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Protonated matrix formation:
M+ +M ----- ► MH+ + (M - H)
The radical formed in the above reaction can be converted into (M - H)' if it reacts 
with a free electron:
(M - H)' + e '  ► (M - H)'
Reactions can also occur between the matrix and the analyte; very often these 
reactions produce protonated species. These are thought to occur after secondary 
proton transfer reactions have taken place in the plume:
MH+ +A   ►M + AH+
The creation of ions by gas phase reactions has been reported as a feasible 
mechanism for ionisation by Wang et al. [44].
1.3.1.4 Energy Pooling
This details the role of MALDI matrix excitation states and explains the energetic 
processes underpinning a 'diffusely excited solid'. The internal energy of two or 
more excited state matrix molecules combine ('pool' together, as represented in the 
equation as M*M*) to form one matrix radical cation (M+) [39].
This approach is conceivable as clusters often form in MALDI plumes; the following 
equations detail the process:
2 hv
MM ---------- ► M*M*  ►M + M+' + e‘
M*M* + A ---------- ► MM + A+’ + e"
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1.3.1.5 Excited-State Proton Transfer
This is a popular theory that involves one photon where a single excited matrix 
molecule (M*) can efficiently transfer a labile proton to the analyte / matrix molecule 
in the ground state [45].
The following equations detail this theory:
M + hv —► M*
M* + A —► (M - H)' + AH+
M* + M —► (M-H)' + MH+
1.3.1.6 Disproportionation Reactions
It is proposed that disproportionation reactions may hold the key to the fact that some 
matrices perform better in positive ion mode and others in negative ion mode [46,47]. 
The following equation displays this theory:
nhv
2M ---------- ► (MM)* ----- ► (M - H)' + MH+
1.3.1.7 Desorption of Preformed Ions
Another proposal is that the ions are preformed and that the laser pulse liberates them 
resulting in their desorption [48].
1.3.1.8 Thermal Ionisation
Thermal ionisation is a very likely mechanism when particle suspension matrices 
have been utilised in the experiment. This is because this particular type of matrix is 
composed of fine particles and these particles do not possess a chromophore or have 
the ability to co-crystallise with the analyte. Thermal ionisation can occur in two
ways: at the particle surface as expressed using the Saha-Langmuir equation [49] or 
via a disproportionation reaction that incorporates the electron affinity of the matrix. 
It has also been inferred that laser-induced damage on the crystalline surface, 
approximately 1 J i m  in thickness, causes desorption of ions to occur. When an IR 
laser is used the laser penetrates much deeper into the sample [39,50].
1.3.2 Secondary Ion Formation
1.3.2.1 Electron Transfer
A feasible reaction in the plume may involve electron transfer; this process is 
detailed in the following equation whereby reactions are thought to occur between 
the matrix radical cation and an analyte molecule:
M+' + A <-► M + A+'
Electron transfer has been put forward as a possible mechanism that is thought to 
occur when the compounds of interest have low ionisation energies [50].
1.3.2.2 Proton Transfer
Gas phase proton transfer reactions with neutral matrix and neutral analyte 
molecules, when the primary ions are radical cations, have been reported [41].
The free energy change (AG) of matrix-analyte and analyte-analyte reactions in the 
plume can be selected in the mass spectrum.
AG = -RTln(K)
K: calculated from the relative abundances of ions in the mass spectrum that are 
thought to be involved in charge transfer reactions in the plume [39,50].
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1.3.2.3 Cationisation
Cationisation is the term given to the process where the analyte is primarily ionised 
by forming metal ion adducts. This has been shown to be a process commonly 
observed with carbohydrates and synthetic polymers [51,52].
Gas-phase cationisation has been an observed reaction in a number of publications 
along with other gas-phase reactions [53'56].
Zhang et al. have investigated the role of the matrix in the cationisation process t56].
1.3.3 Ion Suppression Effects
Matrix suppression of the analyte, brought about by secondary ion reactions, is the 
most common type of suppression that occurs during the MALDI process [57].
Donegan and co-workers successfully managed to reduce the matrix suppression 
effect on small molecules by spray coating the MALDI target plate with a solution 
containing nitrocellulose and alpha-cyano-4-hydroxycinnamic acid (a-CHCA ~1- 
2mg/mL in acetone); however, the experiments performed were limited to 
conventional MALDI analysis. This technique was a different slant on the dried- 
droplet technique, but this method has not been documented for the analysis of tissue 
samples [57].
1.4 The Desorption Process
As with the mechanisms for ionisation, there are many theories put forward as to 
how the desorption process occurs. The thermal spike model details how low laser 
fluence irradiation of the sample results in heating of the sample, causing the 
sublimation of matrix molecules. However, if the laser intensity is increased beyond 
a certain point a rapid increase in desorption efficiency is observed [58]. Another 
desorption hypothesis that has been put forward is the pressure-pulse theory. This is 
based on the pressure gradient that is observed normal to the surface where the 
desorption of large molecules is enhanced by colliding them with high speed matrix
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molecules [59]. More recently, the Quasi thermal model was introduced by 
Hillenkamps' research group where the co-crystallised analyte/matrix combination 
undergoes pressure related decomposition, forming smaller particles. The smaller 
particles (clusters and /or single molecules) are desorbed via thermal effects exerted 
thus creating the MALDI plume where these particles undergo collisions, resulting in 
the formation of the matrix and analyte gas phase species by expansion cooling [60, 
611. An important factor in promoting efficient desorption is thought to be reliant on 
the thermodynamic properties of the matrix. The MALDI response has been shown 
to be affected by sample morphology [62]; this could potentially alter the 
desorption/ablation process.
1.5 The Mass Analyser
There are many different types of mass analyser that operate under high vacuum 
conditions to prevent ions colliding with air molecules.
Nominal-mass analysers have a resolution of approximately 1:1000-2000; 
specificity, however, can be enhanced by the use of high resolution mass 
spectrometers where the resolution can be as high as 1:100 000 giving mass accuracy 
under lppm [63].
1.5.1 The Time-of-Flight Mass Analyser
Developed in the late 1940's by Cameron and co-workers [64], time-of-flight mass 
spectrometry (TOF-MS) is a type of mass spectrometry in which an electric field of 
known strength is used to accelerate the ions. Improvements in mass resolution led 
to the first commercial instrument being introduced in 1955 by Wiley and McLaren
[65]
More recently, TOF-MS has been coupled to MALDI and ESI ionisation methods 
and has been utilised in the development of high resolution instruments such as the 
quadrupole time-of-flight (QTOF) and in other instruments with TOF-TOF 
capabilities. The main features associated with TOF-MS include high sensitivity, 
theoretically unlimited mass range and rapid analysis time [66].
Unlike the quadrupole mass analyser, all the ions of differing m/z values enter the 
time-of-flight at the same time and therefore selected ion monitoring does not 
significantly increase the sensitivity.
1.5.1.1 The Theory Underpinning Time-of-Flight Mass Spectrometry
Time-of-flight separates ions based on their velocity, the time taken to reach the 
detector. Ions with a higher mass travel more slowly than ions of a lower mass and 
multiply charged ions travel faster than singly charged ions [67].
The theory behind the mass analysis is post-acceleration of the ions occurs to a 
constant kinetic energy. The velocity of the ions is an inverse function of the square 
root of their m/z values; the following equation demonstrates this principle:
Mass analysis of ions can be achieved by calculating their time of arrival at the 
detector placed at the end of the flight tube as shown in the following equation:
/  v — vciuunyv = f  2 zV) 1/2 zV = constant kinetic energy 
z = charge on the ion 
V = accelerating potential 
m = mass 
t = time
\  L = length of flight tube
r  ~ \t = L = L m 1/2
v
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1.5.1.1.1 Linear TOF-MS
The ions pass along the field free drift zone and where they are separated according 
to their m/z values. The attainable mass resolution is lower using linear TOF than 
that of reflectron TOF instrumentation; this arises from differences in the velocities 
of ions with the same m/z value [68].
Ionisation
Source
Sample Inlet - • •
Acceleration 
Area Flight Path
• •
Vacuum . 
Chamber
Field Free Drift Zone
Figure 1.4: Schematic Diagram of the Linear Time-of-Flight Instrument 
Arrangement. Ions are separated based on their m/z ratio with lighter ions travelling 
faster than heavier ions and multiply charged ions travelling faster than singly 
charged ions (adapted from [1]).
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1.5.1.1.2 Reflectron TOF-MS
The reflectron TOF, developed in 1973 by Mamyrin and co-workers [69], can be used 
to correct and compensate for the kinetic energy distribution of ions. The ions are 
directed towards a detector by an electrostatic field and ions that possess more 
kinetic energy penetrate deeper into the reflectron that is located at the end of the 
flight tube and have a slightly longer path to travel to reach the detector and the 
opposite of this is true for ions with less kinetic energy. As demonstrated by the 
diagram in figure 1.5 the ions are turned approximately 180° by a fixed potential 
gradient and then reaccelerated back through the reflectron and focussed towards the 
detector [70].
Pulsed Laser
//
Reflectron  
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Plate
Figure 1.5: Schematic Diagram of the Reflectron Time-of-Flight Arrangement
(adapted from |1])
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1.5.2 The Quadrupole Time-of-Flight Mass Analyser
The quadrupole time-of-flight mass analyser, as its name suggests, is a combination 
of the quadrupole mass analyser with the time-of-flight mass analyser [71].
The instrument is comprised of three quadrupoles: QO; Q1 and Q2 and a reflectron 
TOF mass analyser. The QqTOF tandem mass spectrometer can be thought of as a 
triple quadrupole with the last quadrupole (Q2) being replaced with a TOF mass 
analyser. This instrumentation can be interfaced with ESI, APCI and as figure 1.6 
illustrates a MALDI ion source. The main advantage of the quadrupole time-of- 
flight mass analyser is the ability to record all ions in parallel accompanied with high 
resolution and mass accuracy. The purpose of QO is for collisional cooling and for 
the focusing of the ions; both QO and Q2 are only operated in the radio frequency 
(r.f.) mode.
To obtain TOF-MS data Q1 is operated in r.f. mode; MS/MS data is obtained by the 
Q1 being in mass filter mode to enable only the precursor ion of interest to be 
selected.
Q2 is where collision induced dissociation (CID) takes place with gas molecules 
such as nitrogen and argon. Once ions have left the collision cell (Q2) they are re­
accelerated and focussed using ion optics that enters the ion modulator of the TOF 
mass analyser.
A pulsed electric field is used to push the ions orthogonal to their original trajectory 
into the accelerating column. Ions then move into the field free drift zone where they 
are separated based on their mass to charge ratio in the time-of-flight mass analyzer. 
A time-to-digital converter (TDC) is used to record all mass spectra [71].
The higher sensitivity and improved resolution achieved with QTOF instrumentation 
has been demonstrated for the analysis of phosphopeptides by Steen et al.[12\
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Figure 1.6: Schematic Diagram of a Hybrid Quadrupole Time-of-Flight 
Instrument with an Orthogonal MALDI Ion Source. Image supplied by Dr J. 
Wingate, Applied Biosystems/MDS Sciex, taken from the oMALDI Server users 
Manual, MDS Sciex, 2003 [73].
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1.6 Tandem Mass Spectrometry
Tandem mass spectrometry more commonly referred to as MS/MS was first 
implemented in the late 1960’s [74]. MS/MS involves the coupling of two mass 
spectrometers in time and space to obtain more information relating to a sample of 
interest. It can be used to deduce the structure of unknown compounds, for the 
identification of compounds from complex mixtures and to investigate collision 
induced dissociation pathways. The three stages in MS/MS are: mass selection; 
fragmentation via collisions with neutral gas atoms and mass analysis. The four 
main types of scan that can be used for MS/MS analysis are: product ion scans; 
precursor ion scans; constant neutral loss scans and selected reaction monitoring. To 
obtain structural information the product ion scan is the most widespread mode 
whereby the spectrum of the product ions can be obtained from the dissociation of a 
mass-selected precursort75].
1.7 Mass Spectrometry Imaging Techniques
Molecular imaging techniques such as magnetic resonance imaging (MRI) [76] and 
positron emission tomography (PET)[77] are long established; however, the direction 
that the biomedical sciences are taking towards biomarker discovery makes the 
existing techniques somewhat unsuitable. This is mainly because they require 
molecular probes in order to detect a compound of interest; therefore there is not the 
capacity to simultaneously detect many different biomolecules that may be present 
within the sample. In recent years mass spectrometry imaging techniques have 
entered a league of their own in terms of sensitivity, mass accuracy, high-throughput 
and the ability to be used for many different chemically diverse compounds from a 
variety of samples. There are many applications of mass spectrometry imaging 
techniques that encompass the ‘omics’ revolution with a particular emphasis on 
proteomics [78], lipidomics [79,80] and metabolomics [81].
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1.7.1 SIMS Imaging
The earliest mass spectrometry imaging technique was based on SIMS.
SIMS imaging is performed by rastering a focussed narrow diameter primary ion 
beam across the sample surface generating a mass spectrum for each location where 
the beam strikes the sample. With imaging software the culmination of these data 
can be used to produce molecular ion maps by selecting the ion masses of interest 
[20]. This type of mass spectrometry analysis is also referred to in the literature as 
microprobe imaging [82]; this type of imaging is common to both SIMS imaging and 
MALDI MSI.
The sensitivity of SIMS imaging is restricted by the narrow diameter of the primary 
ion beam as this limits the number of secondary ions that can be generated at each 
increment of the analysis [20]. The attainable resolution is determined by the spot size 
of the primary ion beam; 50nm spot sizes are commercially available [83].
SIMS imaging is well-suited for the analysis of small molecules (under lOOODa); 
however, as the m/z value increases the generation of secondary ions decreases. It 
has unparalled spatial resolution in comparison with other mass spectrometry 
imaging techniques and SIMS imaging with subcellular resolution has been reported 
[84,851. Monroe et al. have used SIMS imaging to investigate endogenous compounds 
within spinal cord tissue sections [86]. The localisation of lipids in the aortic wall has 
also been imaged using TOF-SIMS [87].
1.7.2 DESI Imaging
DESI Imaging is a relatively new concept where molecular images can be obtained 
while the sample is in ambient conditions without the need for matrix application.
To obtain images using DESI the sample is mounted onto a target such as a 
microscope slide and is moved under a stationary fixed spray nozzle, generating a 
mass spectrum for each location on the sample. A two-dimensional image is 
obtained when all the data for individual locations are accumulated for selected ion 
(s) [88]. DESI Imaging mass spectrometry has been used to obtain images for the 
distribution of clozapine and its metabolites in a range of rat tissue [89], to study the
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distribution of phospholipids in rat brain sections [90] and liver adenocarcinoma [91]. 
More recently, Kertesz et al. [92] have reported improved imaging resolution of 
approximately 40pm by optimising the most influential parts of the analysis such as 
the distance from the spray tip to the sample and the solvent flow rate.
1.7.3 Matrix-Assisted Laser Desorption Ionisation Mass Spectrometry 
Imaging (MALDI MSI)
MALDI MSI involves firing the laser (pulsed UV of the MALDI ion source), usually 
a nitrogen (337nm) or Nd: YAG (355nm, triple frequency) at increments along the 
sample of interest in a raster pattern and every time the laser fires at a particular 
location on the sample a mass spectrum is generated. The accumulation of these data 
allows many different images to be observed by the selection of different mass to 
charge ratios. The coupling of MALDI with a TOF mass analyser allows for a 
theoretically unlimited mass range to be achieved [66].
1.7.3.1 Microprobe Mode
The conventional approach to MALDI MSI is using microprobe mode where as 
previously described in section 1.7.3 a laser is used to raster over the sample surface 
at set increments and once the imaging experiment has run to completion images can 
be generated and individual spectra from each laser spot can be viewed. The 
achievable image resolution with MALDI MSI is a current limitation of the 
technique. Factors that limit such a resolution in microprobe mode include the laser 
spot size and the sample stage movement[93]. This has prompted researchers such as 
Heeren et al. to investigate ways to improve spatial resolution; this was done using 
the MALDI mass microscope [83,93].
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1.7.3.2 Microscope Mode
Microscope mode in contrast to microprobe mode utilises a two-dimensional detector 
to generate magnified images of the ion distributions in discrete areas within a 
sample. With this mode of mass spectrometry the spatial resolution is determined by 
the quality of the ion optics and the resolving power of the detector rather than the 
laser spot size as with microprobe analysis.
Luxembourg et al. have succesfully demonstrated the concept of MALDI in the 
microscope mode for the analysis of peptide and protein distributions [93]. The 
achievable resolution with this approach is significantly better than with the more 
accepted conventional approach of MALDI in microprobe mode. A lateral 
resolution of 4pm has been reported for the analysis of peptides and proteins [93].
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Figure 1.7: Schematic Diagram of the Microprobe and Microscope Modes of 
Analysis [82].
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1.8 Practical Aspects of MALDI MSI
1.8.1 Instrumentation
The application of MALDI MSI to protein profiling experiments can be achieved 
using conventional MALDI-TOF-MS instrumentation; however, for small molecules 
this is not the instrumentation of choice due to the limitations brought about by the 
instrument configuration. The conventional MALDI-TOF-MS instruments are of 
axial configuration in contrast to instrumentation used for small molecule analysis; 
orthogonal MALDI ion sources on hybrid quadrupole time of flight (QqTOF) 
instruments with tandem MS capabilities. Orthogonal MALDI ion sources ensure 
that the ions are introduced at an angle that is perpendicular to the time-of-flight 
tube; therefore, unevenness in the surface topography of the sample does not affect 
the mass accuracy [94]. With the conventional MALDI-TOF-MS instrumentation the 
time of flight of an ion can be affected by the surface topography and charging 
effects of the sample. For problems relating to the charging effect, sputter coating 
with metals such as gold has greatly improved the data generated [95]. The QqTOF 
with an orthogonal MALDI ion source offers good mass measurement stability and 
the potential to perform tandem MS experiments.
1.8.2 UV Lasers for MALDI MSI
The most widely incorporated lasers in MALDI are Nitrogen (N2, ^=337nm) and 
frequency tripled Neodymium: Yttrium Aluminium Garnet (Nd: YAG, ?i=355nm). 
The N2 laser is the most commonly used laser for MALDI analysis; this is probably 
due to the low cost associated with this type of laser. The incorporation of solid state 
lasers such as the Nd: YAG into MALDI instrumentation has become more popular 
due to the higher repetition rates associated with the laser; for example, up to 1kHz is 
achievable with an Nd:YAG laser in comparison with 20Hz on a standard N 2 laser 
t96]. The wavelength at which the nitrogen laser operates makes it more amenable to 
a wider selection of matrices than the frequency tripled Nd: YAG. However, the 
higher repetition rates associated with the Nd:YAG laser have made it a popular 
choice. Investigations conducted by Holle et al. have shown that the narrow
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gaussian beam profile can result in reduced sensitivity. They have overcome this 
problem by modifying the frequency tripled Nd: YAG laser to a structured beam 
profile C97].
1.8.3 IR Lasers
1.8.3.1 IR MALDI MS
In contrast to UV MALDI, where the laser energy deposition proceeds through 
electron excitation, IR MALDI operates through vibration mechanisms [98].
The first published result of using an IR laser for MALDI was by Overberg et al. [99]. 
The matrices of choice for this type of laser are liquids such as glycerol. This is 
because more sample is consumed by each laser shot than in UV MALDI; thus the 
application of a solid matrix to the sample surface would somewhat limit the amount 
of data that could be generated. IR MALDI is not as sensitive as UV MALDI; this 
was demonstrated in the work conducted by Berkenkamp et a l  [100]. The IR lasers 
are also considerably more expensive to implement than the commonly incorporated 
N2 lasers in UV MALDI[,01).
1.8.3.2 Infrared Laser Desorption Ionisation (IR LDI)
A recent review article by Peterson tl02] highlighted the fact that many researchers are 
looking into ways that efficient ionisation from complex biological samples may be 
achieved without the use of a chemical matrix. This is particularly important for 
small molecule analysis as the matrix background signals can hinder the 
interpretation of the data. The use of infrared lasers has abolished the requirement of 
the matrix for the analysis of certain samples, for example some plant material as this 
type of tissue contains residual water. Erbium: Yttrium aluminium garnet (Er:YAG) 
lasers are infrared lasers that emit light with a wavelength of 2.94pm. The frequency 
of the Er: YAG laser overlaps with the resonant band of water O-H vibrations. 
Therefore, this type of laser is good for samples that contain residual water as the
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water takes the role of the matrix in absorbing the laser energy and thus promoting 
the ionisation. A major advantage of using the Er: YAG laser is the elimination of 
interfering matrix peaks. IR LDI MS has been used for the molecular profiling of rat 
brain tissue sections [103], seeds, fruits and whole oils [104].
1.8.4 Sample Preparation Strategies for MALDI MSI
In the last decade, advances have been made in MALDI MSI; however, there are still 
some fundamental issues that need to be addressed with the main emphasis being on 
the sample preparation procedure. The sample preparation procedure, storage and 
handling of samples are some of the most important factors in MALDI MSI and 
controlling these variables is more likely to generate analytical results that are 
reproducible.
There are many different techniques and methods used for sample preparation but 
these can vary for individual compounds. Hence, to achieve the highest quality, 
reproducible results the sample preparation procedure must be optimized for each 
analyte of interest.
1.8.4.1 Tissue Preparation for Direct and Indirect Analyses
In order to achieve good, reproducible results tissue should be stored and prepared in 
a suitable manner[105,106].
The majority of imaging experiments have been conducted on biological tissue 
samples -  either to study endogenous compounds, for example the study of diseased 
tissue and for the identification of biomarkers related to diseased state tissue [107], or 
for the detection of a particular compound such as an administered pharmaceutical 
compound [108].
The removal and storage of tissue are important factors in maintaining the spatial 
resolution of compounds. Tissue samples need to be removed in such a way that the 
native shape of the tissue is preserved as much is possible; this is usually achieved by 
snap freezing the sample using nitrogen-cooled isopentane.
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The most important factors in tissue sectioning are tissue thickness, temperature and 
the use of fixing media [105, 109]. Cryosectioning is performed to obtain a tissue 
section that is suitable for analysis. Fixing media such as optimum cutting 
temperature (OCT) [105] are used to mount the sample onto the sample stage prior to 
sectioning. OCT has been reported to cause ion suppression effects in MALDI and 
should be avoided where possible [105, 110]. The use of carboxymethyl cellulose 
(CMC) has been demonstrated to be a good embedding media that does not interfere 
with MALDI analysis [111]. The environmental conditions within the cryostat should 
be optimized for the type of tissue; for example, fatty tissues tend to require a lower 
temperature to obtain better quality sections. Tissue thickness has been shown to be 
an influential factor; thicker tissue sections are easier to cut and handle but are less 
electrically conductive in the mass spectrometer. The opposite of this is true for 
thinner sections. It has been found that for MALDI Imaging the optimum tissue 
thickness for direct analysis is ~10-20jim - this thickness is sufficient to expose the 
intracellular contents of the cells within the tissue [112]. Research has shown that thin 
sections are also required for the optimal ionisation of both the analyte and matrix 
[1051. After sectioning, the tissue should be mounted on a surface which is 
electrically conductive such as an aluminium plate or directly onto the MALDI target 
plate for analysis. Tissue sections should be mounted quickly and stored at -80°C 
prior to analysis as allowing the sample to warm has been reported to have a 
substantial impact on the data generated and its reproducibility [107]. It is important 
that when transferring the tissue to the plate that the native shape of the tissue is 
maintained and that the tissue is not tom or distorted in any way.
1.8.4.1.1 Direct Tissue Analysis
Direct tissue analysis is usually performed to maintain the spatial resolution of 
compounds. It is advantageous in comparison with indirect tissue analysis as there is 
minimal handling of the sample, and therefore less room for error or analyte losses. 
An example of direct tissue analysis can be seen in the research of Hsieh et al. [113]. 
They conducted a study to measure Clozapine in rat brain tissue using sinapinic acid 
as a matrix as this crystallises better over tissue than a-CHCA.
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Direct tissue analysis can be problematic when using organic matrices as the co­
crystallisation between the analyte of interest and the matrix may be hindered due to 
the presence of endogenous compounds within the tissue or by a high salt content.
1.8.4.1.2 Indirect Tissue Analysis - Blotting Methods
To overcome the problems that are associated with direct tissue analysis, a blotting 
method, a form of indirect tissue analysis, can be adopted.
Research by Chaurand et al. [114] has shown that carbon-filled polyethylene 
membranes were suitable for use in MALDI as they showed good electrical 
conductivity and the ability to blot proteins due to their hydrophobic surfaces without 
loss of spatial resolution. Nylon [ll5], nitrocellulose [ll6] and more recently cellulose 
[117] have been investigated as potential blotting membranes.
Bunch et al. (2004) [117] investigated pharmaceutical compounds in skin indirectly 
using MALDI by using a blotting method that involved the coating of cellulose 
membranes with the matrix and then blotting the treated skin sample onto the 
membrane. In order to get the highest quality image the blotting membrane and the 
matrix must be suited to the analyte. More recently, Prideaux et al. have reported the 
imaging of xenobiotic compounds in skin by indirect MALDI M S I[l l8].
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Figure 1.8: Schematic Diagram of the Blotting and Direct Tissue Procedures.
Adapted from Todd et al. [119].
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1.8.4.2 Matrix Selection
Selection of the most suitable matrix is imperative to obtain high quality results with 
MALDI in conjunction with the optimisation of sample preparation; these are 
essentially the most important parameters of MALDI analysis.
Due to the majority of MALDI matrices having low molecular weights, most 
MALDI analyses until recently concentrated on large molecules, typically >1500Da. 
Cohen and Gusev [120] conducted a series of experiments to assess the suitability of 
MALDI for small molecule analysis. They recommended the selection of a matrix 
that does not directly interfere in the same mass region of the spectrum as the analyte 
or alternatively the use of a high molecular weight or inorganic matrix. However, 
these approaches are only valid for when the analyte information is already known 
and would still pose problems for analyses such as metabolomic applications. The 
main requirements of a MALDI matrix is co-crystallisation (organic matrices) with 
the analyte; the matrix must be soluble in the solvent in which the analyte is 
dissolved in, absorb at the laser wavelength, be stable under vacuum and ultimately 
promote ionisation At present there are no protocols as to how to select the best 
matrix for a particular application. Zenobi et a l  [50] proposed guidelines for matrix 
selection based on ion formation mechanisms; however, research is still being 
conducted into matrix crystallisation and the analyte incorporation process. In the 
past, many different compounds were empirically tested for their suitability to act as 
a MALDI matrix. However, at present there are relatively few matrices available 
that yield reproducible, high quality mass spectra. The most common MALDI 
matrices are the cinnamic and benzoic acid derivatives; these were documented as 
good MALDI matrices for proteins in the late 1980's [121].
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Figure 1.9: The Chemical Structures of Established MALDI Matrices.
- 3 1  -
The organic acid matrices depicted in figure 1.9 all contain chromophores and it is 
this part of the organic compound that absorbs the laser energy. Organic acid 
matrices are good for positive ion mode MALDI; this is because they have acidic 
properties and thus are characterised as proton donors. As most analyses are 
performed in this mode, this type of matrix has become a popular choice.
Organic acids such as 2, 5-dihydroxybenzoic acid (DHB), alpha-Cyano-4- 
hydroxycinnamic acid (a-CHCA) and sinapinic acid (SA) are routinely used in the 
analysis of proteins. a-CHCA, characterised by its ability to form small homogenous 
crystals has also proven a good matrix for the analysis of small compounds such as 
pharmaceutical products. 3-hydroxypicolinic acid (3-HPA) is good for 
oligonucleotide analysis and ferulic acid (FA) is good for peptide/protein analysis 
[122]. The concentration of matrices is based on the solubility of the matrix and the 
efficiency of the matrix to promote ionisation. Organic matrices are typically made 
to a concentration of ~10-25mg/mL in a suitable solvent that the matrix and analyte 
will be soluble in. However, the main disadvantage associated with the use of 
organic acid matrices is that they produce lots of background noise in the low mass 
region due to matrix clusters and fragment ions leading to interfering peaks, which 
can sometimes make it difficult to isolate the peaks of interest associated with the 
analyte. For most organic matrices, the background noise from the matrix peaks 
occurs in the low mass region [123] which can coincide with compounds such as 
pharmaceutical products and metabolites as these often have low molecular weights. 
For compounds that are not suited to positive ion analysis, negative ion mode 
MALDI can be performed. 9-aminoacridine (9-AA) is a matrix that has been 
reported to be a good matrix for negative ion mode MALDI as it contains one basic 
group and it has a conjugated ring system. As 9-AA is a strong base it accepts 
protons, resulting in the formation of [M-H]' ions. This chemical feature makes it a 
good matrix for the analysis of compounds in negative ion mode and superseded the 
conventional organic acid matrices for this application. 9-AA has been used to 
analyse proteins [124] and for the metabolomic analysis of eukaryotic tissue [125]. 
Edwards and Kennedy detected 105 metabolites using this matrix in negative ion 
mode and they achieved good detection limits for the standards (in the nanomolar to 
micromolar range)[125].
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Although MALDI MSI has emerged as an excellent molecular imaging technique its 
use in biological tissue analysis is somewhat hindered by the lack of suitability of the 
matrix and the crystallisation processes on tissue surfaces that contain endogenous 
salts. Different matrices form different types of crystals and the choice of matrix is 
dependent on the analyte as not all matrices have the same capacity to instigate the 
ionisation of a particular analyte. The choice of solvent that the matrix is dissolved 
in is also important; the solvent is usually selected based on the solubility of the 
matrix and the analyte.
To overcome these problems tissue washing to remove endogenous compounds such 
as salts has been reported; this washing procedure is generally accepted for large 
molecules such as peptides and proteins. However, for small molecule analysis, this 
could cause significant translocation of the compounds of interest or if the compound 
is soluble in the washing solvent, it could be lost altogether. If the conventional solid 
organic matrices are not suitable for a particular type of analysis due to interfering 
peaks in the area of interest, the potential of ionic liquid matrices along with particle 
suspension matrices has been investigated in an attempt to offer an alternative 
solution. Ionic liquid matrices are prepared by mixing an acidic MALDI matrix and 
an organic base in equimolar concentrations [126,127]. They are compatible with both 
polar and non polar analytes [,20] and they do not produce areas with high signal 
intensity (hotspots). However, their use is correlated with poor ionization efficiency 
and interfering peaks and low mass resolution [128]. Liquid matrices are commonly 
incorporated into IR MALDI MS methods [129].
1.8.4.2.1 Particle Suspension Matrices
First introduced by Tanaka et al. in 1988 [12], particle suspension matrices are 
composed of metal particles that are suspended in solution. More recently particle 
suspensions have been re-evaluated for their potential role in MALDI analyses t130' 
132l  Their mode of action is different from that of organic acids in that co­
crystallisation does not occur between the matrix and the analyte. It is thought that 
particle suspension matrices work by a thermal ionisation mechanism. In positive 
ion mode, graphite-based matrices induce strong cationisation of sodium, and
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potassium, hence the formation of sodium and potassium adducts is more prevalent 
than the formation of the molecular ion species. The potential limitation with particle 
suspension matrices is that the matrix is thought to promote increased fragmentation 
of the analyte and lower sensitivity [63]. However, it is important to stress that the 
choice of matrix is influenced by the nature of the sample. Thus if the conventional 
matrices are unsuitable, a compromise has to be reached.
Crecelius et al. [132] investigated the use of particle suspension matrices for the 
analysis of tetracycline antibiotics utilising concentrations of approximately 
lOmg/mL in a solvent solution in which the particles will form a suspension, for 
example ethanol. The particle suspension mix incorporated ethylene glycol to act as 
a dispersant and an acid such as trifluroacetic acid (TFA) is often added to enhance 
the ionisation of the analyte. More recently Black et al. [133] have done some 
research into the use of pencil lead as a matrix and as an internal calibrant, and for 
the analysis of peptides and polymers.
1.8.4.2.2 Matrix Application
The deposition of the chemical matrix is a critical factor in achieving reproducible 
data using MALDI M S I[134]. There are many different ways that the matrix can be 
applied to the sample and, depending on which method of application is chosen, this 
also affects the concentration of the matrix to be prepared. The matrix can be 
applied either to coat the entire surface of the sample or in an ordered array of 
discrete spots across the surface.
Endogenous compounds contained within samples can promote adduct formation, 
poor crystallisation of the matrix and ion suppression effects. The type of sample to 
be analysed may also affect the spectral quality from spot to spot due to the 
heterogeneity within the tissue i.e. in some parts of the tissue suppression effects may 
be more evident due to a higher concentration of endogenous compounds.
For biological tissue analysis, it is important to have the matrix homogenously 
distributed on the surface of the tissue in order to ensure that the results obtained
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reflect the biological characteristics of the sample and not uneven matrix coverage
[135]
1.8.4.2.3 Manual Spotting
The matrix can be deposited in discrete spots by manually pipetting a small amount 
(lpL) directly onto the tissue surface [105,112].
1.8.4.2.4 Airspray Deposition
This method employs an airbrush that is connected to a compressor, thus allowing 
the pressure at which the matrix is applied to be controlled. The matrix application 
process with this particular device is controlled manually; therefore the operator has 
to make a judgement as to whether the matrix coverage is homogenous and this is 
prone to human error. It is very important to minimise sample wetting when 
applying the matrix as this can cause migration of the analytes within the tissue 
section and therefore not provide reliable data when imaging experiments are 
performed [117].
Electrospray matrix deposition has also been reported where the matrix crystal 
formation and size were influenced by the spray voltage and the distance from the 
sample tl36]. Oscillating capillary nebulisers have also been reported to produce 
homogenous matrix coverage tl34].
It is thought that the droplet size of the matrix from manual spraying is much larger 
than what can be achieved with an automated spray, giving rise to poorer crystal 
formation [135].
1.8.4.2.5 Automated Matrix Spotters
Automated matrix spotters were introduced to combat the potential human error and 
sample wetting associated with applying the matrix manually. However, the major
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limitation to the implementation of some of these instruments into laboratories is the 
expense; this has led some researchers, for example Baluya et a l  [137], to modify 
inexpensive commercial inkjet printers. These printers have shown to be an 
improvement on the manual techniques still employed by many laboratories. A 
potential problem associated with this type of modification is the compatibility of the 
solvents used to prepare matrices with the plastic containers contained within the 
printer; plasticiser contamination is an impending problem.
A few examples of commercially available automated matrix spotters that have been 
used in MALDI MSI experiments are the Shimazdu Chip, Bruker image Prep, 
Suncollect and Labcyte Portrait 630. The Shimadzu Chip uses piezoelectric 
technology to deliver pico-litre volumes of matrix onto preselected regions of the 
sample surface without contact with the sample [138]. The Bruker ImagePrep system 
also uses piezoelectric technology to create a matrix aerosol with an achievable 
droplet size of 20pm. The matrix application process is controlled by a light 
scattering sensor [139].
The Suncollect system operates using a needle to deposit pre-determined quantities 
onto the sample surface; however, the limitation with this type of instrument includes 
having to use lower concentrations of matrix to avoid blocking of the needle and the 
fact that matrix can crystallise around the needle and thus interfere with matrix 
deposition. The Suncollect matrix deposition device also can be adapted to spray 
coat the samples - this is more beneficial for imaging experiments than for profiling 
experiments [140]. The Labcyte Portrait 630 avoids these problems by employing a 
unique acoustic technology in which sound energy is used to transfer very small 
droplets of matrix to the sample. This ensures that there is no contact with the 
sample on transferral of the matrix and the matrix concentration can be varied as 
there is no needle to become blocked. The benefits of this type of sample 
preparation include prevention of the movement of biomolecules, the ability to 
control the drying time of the matrix and the number of passes of matrix. The user 
therefore has the ability to calculate how much matrix has been deposited in one 
position and the enhanced crystal formation and spot size produce more reliable and 
reproducible mass spectra [134].
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1.9 Applications of MALDI MSI
MALDI MSI is an emerging technique for investigating molecular distributions 
within biological systems through the analysis of thin tissue sections and hundreds of 
compounds can be measured in a single MALDI imaging experiment. The first 
major application of MALDI MS was for the analysis of proteins and peptides. 
Caprioli et al. introduced MALDI MSI in 1997 with their work detailing the direct 
profiling of analytes within tissue sections [141]. MALDI in contrast to many other 
techniques is tolerant of contaminants such as buffers and salts, gives good 
sensitivity and produces relatively simple spectra with most ions being singly 
charged, sodiated or potassiated. Since the introduction of MALDI MSI, research 
has moved towards biomedical applications, for example mapping disease 
biomarkers, and in pharmaceutical research, for example mapping pharmaceutical 
compounds in tissue [142]. This is because spatial information on the distribution of 
pharmaceutical compounds in tissue is a very important aspect in assessing drug 
efficiency. Conventionally this was done using a combination of 
autoradioluminography and metabolite data obtained from techniques such as liquid 
chromatography (LC)/MS. The main problem associated with this technique is that 
the compound must be radiolabelled and current technology does not allow for the 
differentiation between the compound of interest and its metabolites. MALDI MSI 
has been investigated by Stoekli et a l  as a potential technique to complement whole- 
body autoradioluminography. MALDI MSI allows for the detection of both the 
compound of interest and its metabolites without the need for a radiolabelled 
compound [111]. The fast analysis time and the specificity of MALDI analysis make 
it an ideal technique for such analysis. Hsieh et a l  [142] have also conducted research 
into mapping pharmaceutical compounds in tissue using MALDI MSI. High 
performance liquid chromatography HPLC-MS/MS is a common technique used in 
drug analysis applications; however, this technique does not provide information 
relating to the distribution of the compound in tissues and organs, unlike MALDI 
MSI.
MALDI MSI has been demonstrated as a suitable technique for a diverse range of 
samples; xenobiotic compounds in skin have been analysed using indirect MALDI
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MSI by Prideaux et al.[m] and MALDI MSI has also been applied to plant science 
to investigate agrochemicals (Mesotrione and Azoxystrobin) in soya plants [143].
1.10 Data Interpretation and Analysis
Specialised software packages are commercially available for MALDI MSI; the 
software is responsible for both the control of the instrument and the processing of 
the data once it has been successfully acquired.
MALDI MSI analyses often generate large complex datasets where an image can 
consist of thousands of spectra; the ion intensities can vary in each spectrum along 
with the masses observed. The data generated by MALDI MSI can contain a wealth 
of valuable information. Conventionally MALDI MSI experiments have focussed on 
the analysis of known compounds of scientific interest. However, for studies where 
there may be subtle differences, for example a comparison between healthy and 
diseased tissues, there needs to be established methodology to analyse such complex 
datasets in which these differences can be pinpointed and accounted for. The most 
common statistical approaches include hierarchical cluster analysis and principal 
component analysis. Hierarchical cluster analysis is a technique where the mass 
spectra are clustered on the basis of their similarity and are presented in the form of a 
dendrogram; this has been applied to MALDI MSI data for the analysis of human
r 1441cancer tissue sections 1 J.
Principal Component Analysis (PCA) is used for the simplification and reduction of 
multidimensional datasets [145] in which a new coordinate system is created for the 
dataset based on a linear transformation; the first principal component (this is the 
greatest variance) is found on the first axis and the second largest variance on the 
second axis and so forth. Data are presented in the form of a scores plot and a 
loadings plot. The scores plot assigns a score, in this example the detected m/z value 
along with its corresponding ion intensity imported into the software, that represents 
the weighting each principal component has within the sample. The loadings plot 
presents data with respect to its own influence in each principal component 
allocation. PCA is a more sophisticated way of looking at large datasets generated
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by MALDI MSI with the major goal being the identification of trends in the dataset 
that are not obvious without this type of analysis [146].
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1.11 Aims of Thesis
The overall aim of the work reported in this thesis was to develop methodologies and 
sample preparation strategies for the application of MALDI MSI for small molecule 
analysis from a range of samples. This includes:
Pharmaceutical Compound Analysis:
■ Evaluation of MALDI MSI sample preparation procedures for the analysis of 
anti-asthmatic compounds in lung tissue.
■ To investigate the application of MALDI MSI for the evaluation of 
pharmaceutical dosage forms. Tablets have been directly analysed in order to 
assess the homogeneity of the active drug component throughout the 
excipients. This can provide important information that relates back to the 
formulation process.
Metabolomics:
■ Evaluation of MALDI MSI for metabolomic studies in plant tissue using 
wheat as the model system. The endogenous compounds within wheat grain 
sections were analysed and imaged in order to gain a greater understanding of 
the complex biological processes.
■ To establish methodology for the study of Chronic Experimental Allergic 
Encephalomyelitis; the animal model of multiple sclerosis. The mouse model 
was investigated; spinal cord analysis of diseased tissue alongside control 
tissue was analysed for potential biomarkers related to the disease 
pathogenesis.
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Chapter 2
Evaluation of MALDI MSI Sample 
Preparation Procedures for the Analysis of 
Anti-Asthmatic Compounds in Lung Tissue
2.1 Introduction
Asthma is a chronic disease that causes inflammation in the airways particularly in 
the lungs. In the UK alone there are 5.4 million people currently receiving treatment 
for asthma, therefore it is of great interest to the pharmaceutical industry to develop 
better medications to relieve the symptoms [1]. During an asthma attack, the muscles 
around the airways constrict, causing the airways to become narrower; the lining of 
the airways become inflamed and mucus starts to accumulate in the airways further 
constricting airflow [I].
Asthma drugs have to be inhaled in order to be effective and this is usually achieved 
by the use of pressurised metered inhalers or nebulisers, which create a fine mist of 
the drug. Inhaled corticosteroids (ICS) such as Budesonide and Fluticasone 
Propionate are crucial in the management of asthma as they play a key role in 
reducing inflammation and ultimately improving the function of the lungs. The 
clinical effectiveness of corticosteroids is brought about by their ability to block the 
multiple inflammatory pathways that characterise asthma and other chronic 
inflammatory airway diseases [2, 3]. Inhaled corticosteroids are also used in the 
treatment of chronic obstructive pulmonary disease (COPD) [4]. Long acting beta 2 
adrenergic receptor agonists, for example Salmeterol, are often used in conjunction 
with the corticosteroid drugs. When inhaled, Salmeterol causes the smooth muscle 
in the airways to relax leading to bronchodilation and provides some relief from the 
asthma attack [5]. The use of combination therapies incorporating the use of a 
corticosteroid with a bronchodilator is becoming increasingly common in the 
treatment of asthma, for example Seretide, a combination of Fluticasone Propionate 
with Salmeterol. Once inhaled, there are many factors that can affect the drug’s 
efficacy such as its half-life, its lipophilicity and the distribution of the drug in the 
lungs[6].
The aim of inhaled drug therapies is to attain high local concentrations in the lungs 
and limit systemic exposure. The distribution of inhaled asthma drugs in the lung 
can be related to how effective the drug is in having its therapeutic effect. There are 
many factors that can affect drug distribution in the lungs such as the type of
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compound inhaled, the way in which the compound was inhaled and the condition of 
the airways.
In addition to the actual drug distribution another important factor is how quickly the 
drug is cleared from the lung after bringing about its therapeutic effect.
Techniques that are commonly employed for drug distribution studies include PET
[7], M R I[8] and autoradiography. PET and MRI are techniques that can be used in 
vivo although the achievable spatial resolution is only in the range of millimeters. 
However, for PET there is a requirement for the compound of interest to be 
radiolabelled. Autoradiography has better resolution than PET and MRI (in the 
range of micrometers); however, there is still a requirement for the compound of 
interest to be radiolabelled. Whole body autoradiographyt9] has been demonstrated; 
however, the main drawback with this technique is the cost and, as it is the 
radioactive label that is measured, it can be difficult to differentiate between the drug 
and its metabolites.
Stoeckli et al. [10] have compared autoradiography with MALDI MSI; the sensitivity 
and speed of a MALDI imaging experiment and the ability to differentiate between a 
compound and its metabolites have made MALDI MSI complementary to existing 
techniques. A comparison has also been reported between DESI MS and 
autoradiography, where the distribution of Propanolol was measured in a range of 
organs [11].
Methods that have previously been used to assess drug distribution in the lungs 
include gamma scintigraphy [12] and LC-MS/MS which has been used to study the 
pulmonary disposition of three compounds used in the treatment of asthma by 
measuring the levels of drug in the perfusate tl3].
In this chapter methodology is detailed for the direct and indirect analysis of anti­
asthmatic compound in lung tissue. The indirect analysis of pharmaceutical 
compounds in tissue has been previously described by Bunch et al. for the analysis of 
pharmaceutical compounds in skin [14].
In the work reported in this chapter the potential of MALDI MSI has been 
investigated for the study of a number of compounds. The following sections detail 
these.
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2.1.1 Budesonide
Budesonide has been reported to undergo rapid and reversible intracellular 
esterification with long chain fatty acids in the airway tissue in animal studies [15] and 
also in human studies [16] using radioactively labelled Budesonide. It was reported in 
the animal studies that 80% of the administered radioactively labelled Budesonide 
was found as esters, predominatly as Budesonide Oleate [15]. It is thought that this 
fatty acid conjugation explains why the effects of Budesonide are long lasting.
OH
HQ
Figure 2.1: The Chemical Structure of Budesonide
IUPAC name: 16,17-(butylidenebis(oxy))-l 1,21-dihydroxy-, (ll-p,16-a)-pregna- 
1,4-diene-3,20-dione
Formula: C25H34O6
RMM: 430.24
2.1.2 Fluticasone Propionate
Unlike Budesonide, Fluticasone Propionate does not undergo esterification. 
Undissolved Fluticasone Propionate particles have been reported in the airway lumen 
at periods up to 22 hours after inhalation [16]. Clearly the undissolved particles are
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not going to bring about a pharmacological effect; this is because the drug is not 
accessible to intracellular glucocorticoid receptors [16].
HQ
F
Figure 2.2: The Chemical Structure of Fluticasone Propionate.
IUPAC name: S-(fluoromethyl)-6a,9-difluoro-l 1 p, 17-dihydroxy- 16a-methyl-3- 
oxoandrosta-1, 4-diene-17(3-carbothioate, 17-propionate
Formula: C2 5H3 1F3O5S
RMM: 500.18
2.1.3 Salmeterol
Salmeterol has a long half life of approximately 12 hours; this is related to its 
chemical structure in that it has a lipophilic tail that facilitates its binding and 
resulting accumulation in the cytoplasmic membrane, thus bringing about a 
prolonged P2 receptor stimulation [17].
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.OH
OHHO.
Figure 2.3: The Chemical Structure of Salmeterol.
IUPAC name: 2-(hydroxymethyl)-4-{ 1-hydroxy-2-[6-(4-phenylbutoxy) 
hexylamino] ethyl} phenol
Formula: C25H37NO4
RMM: 415.27
2.1.4 GSK256066B
The test compound was supplied by GlaxoSmithKline (GSK). The structure of this 
chemical compound is confidential.
2.2 Experimental
2.2.1 Materials
Budesonide, Salmeterol, Fluticasone Propionate (FP) and GSK256066B were 
supplied by GlaxoSmithKline (GSK), Stevenage, UK. a-cyano-4-hydroxycinnamic 
acid (a-CHCA), titanium dioxide (Ti0 2 ) and graphite, ethylene glycol, ethanol and 
trifluoroacetic acid (TFA) were purchased from Sigma Aldrich, Dorset, UK
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2.2.2 Methodology
2.2.2.1 Preliminary Matrix Investigations
Preliminary MALDI MS experiments were conducted using the conventional dried 
droplet technique to assess each of the drugs with different matrices in order to select 
the most appropriate matrix for each compound. This was achieved by mixing lpL  
of the drug compound with lpL of the matrix solution and then spotting lpL of the 
combined solution onto a MALDI spot target for analysis. Each drug compound was 
prepared in the following concentrations using 95% ethanol: lmg/mL, O.lmg/mL 
and O.Olmg/mL. This range of concentrations was used to assess the different levels 
of detection for each drug compound. The matrices tested were dissolved in the 
same solvent as the drug to aid the co-crystallisation process. a-CHCA was made to 
a concentration of 25mg/mL in 95% ethanol containing 0.1% TFA.
Particle suspension matrices were also investigated in the same way and were 
optimised for the direct tissue experiments. The optimum particle suspension matrix 
was found to be a mixture of TiC>2 and graphite made to a total concentration of 
lOmg/mL (6 mg TiC>2 and 4mg graphite) containing 0.1% TFA and 0.01% ethylene 
glycol. The TFA was added to enhance the formation of protonated species and the 
ethylene glycol was added as a dispersant. The matrix was applied using an airbrush 
as detailed in section 2.2.2.4.
2.2.2.2 Preparation of Rat Lung Tissue
Laboratory rats (male Wistar rats, supplied by Biological Services, University of 
Sheffield, Beech Hill Road, Sheffield, S10 2RX) were sacrificed by the schedule one 
method of the Home Office, UK regulations. Immediately after the animals had been 
sacrificed the lung tissue was dissected out and immediately frozen using isopentane 
and liquid nitrogen. A cryostat (Leica CM1510) with chamber temperature: -20°C 
was used to section the lung tissue to a thickness of 2 0 pm and then the sections were 
thaw mounted onto aluminium plates. This was followed by the spiking of the tissue 
for all the compounds investigated and matrix application.
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2.2.2.3 Methods for Drug Analysis on Lung Tissue
2.2.2.3.1 Direct Analysis
lpL of each of the different concentrations drug solutions prepared as stated in
2.2.2.1 was applied to separate lung tissue sections prepared as stated in 22.2.2. 
Once the drug spots had dried, the matrix was applied (refer to section 2.2.2.4). The 
drug compounds were applied to different regions of the lung tissue section to 
evaluate potential regional suppression effects. Total drug concentrations equate to 
lpg, lOOng and lOng on the tissue surface.
2.2.2.3.2 Indirect Analysis
Fresh lung tissue was spiked with each of the different concentrations of the drug 
compounds and left on the tissue for approximately two hours, after which time a 
cellulose blot was taken by pressing the cellulose membrane against the tissue 
surface for a 40 second period. This was found to be the optimal blotting time for 
efficient analyte transfer from the tissue onto the cellulose membrane. This 
membrane was then coated with matrix (refer to section 2.2.2.4). Total drug 
concentrations equate to lpg, lOOng and lOng on the tissue surface; however, the 
total amount of drug recovered is dependent on the efficiency of the blotting 
procedure.
2.2.2.4 Matrix Application
Matrix was applied using an airspray deposition technique; one coating cycle 
comprised 5 sprays over the surface of the tissue with a spray distance of 
approximately 10 inches from the tissue surface. Five cycles were needed to achieve 
a homogenous layer of matrix over the tissue surface.
Some of the tissue samples described in this chapter were sputter coated with gold in 
an attempt to increase sensitivity (refer to section 2.3.2). Approximately 5nm of gold 
was deposited directly after matrix application using an Emitech SC7620 mini 
sputter coater (Materials and Engineering Institute, Sheffield Hallam University).
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2.2.3 Instrumentation
All analyses were performed in positive ion mode on an Applied Biosystems/MDS 
Sciex hybrid quadrupole time-of-flight mass spectrometer (Q-Star Pulsar-/) with an 
orthogonal MALDI ion source and a high repetition Nd: YAG laser (1 kHz). The 
Nd: YAG laser has an elliptical spot size of 100x150pm. Images were obtained at a 
resolution of 150 x 150pm. The laser fired at a power of 30% (3.2pJ) at each 
location for 2  seconds.
2.3 Results and Discussion
2.3.1 Budesonide
The mass spectrum in figure 2.4 represents the initial data obtained from 
conventional MALDI MS experiments.
3.9903^
m /z
Figure 2.4: MALDI Mass Spectrum of Budesonide. A representative full scan 
positive ion MALDI mass spectrum for Budesonide (500ng on the MALDI target 
plate) with a-CHCA showing the protonated molecule at m/z 431 and sodiated 
molecule at m/z 453.
- 6 4 -
The direct imaging of Budesonide from lung tissue could not be achieved using 
either organic matrices such as a-CHCA or inorganic particle suspension matrices 
such as TiCb/graphite. Therefore, an indirect blotting method was incorporated into 
the analysis to investigate if the drug could be detected from the surface of the lung 
tissue. The lung tissue contains sufficient moisture to aid the transfer of the drug 
compound to the blotting medium. This allows organic acid matrices to be used as 
the endogenous compounds are not present in sufficient quantity to prevent matrix 
crystallisation or suppress ionisation of the drug compound.
The results of this procedure can be seen in figure 2.5. In this example, the data were 
normalised with the corresponding protonated matrix peak at m/z 190. The total 
drug concentration in the image shown in figure 2.5 is lpg. The circled area shows 
the presence of the drug although there is some evidence of lateral diffusion of the 
drug. This may have occurred during the transfer of the drug from the tissue onto the 
membrane or during matrix application.
Width (mm)
Figure 2.5: Indirect MALDI MS Image of Budesonide.
The amount of the drug on the tissue surface is lpg. The [M+H]+ at m/z 431 of 
Budesonide was normalised with the [M+H]+ of a-CHCA at m/z 190. The circled 
area shows the drug spiked area. The scale on the right hand side of the image shows 
the intensity with white being the most intense (i.e. accounting for more ions) and the 
darker colour accounting for fewer ions.
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2.3.2 Fluticasone Propionate
As previously mentioned in section 2.1.2 there has been evidence reported to support 
the fact that Fluticasone Propionate remains in the lung in its particle form [l5]. 
Attempts to image Fluticasone Propionate are reported in this section. Initially the 
TiCF/Graphite matrix was used for the analysis of Fluticasone Propionate in lung 
tissue. The results are presented in figure 2.6 where the spots are labelled 1, 2 and 3. 
Spots 1 and 2 are not as clearly defined as spot 3; this could be due to regional 
suppression effects within the lung tissue. There is evidence of lateral diffusion; this 
could be due to the choice of solvent used to dissolve the drug but the matrix 
application procedure can also cause the diffusion of analytes on tissue samples [18].
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Figure 2.6: Direct MALDI MS Image of Fluticasone Propionate on Lung
Tissue. The drug concentration of each spot is 1 pg. The potassiated molecule is the 
most predominant ion at m/z 539. The matrix used was TiCF/Graphite prepared as 
stated in 2.2.2.1. The image shows evidence of lateral diffusion within the drug 
spiked areas highlighted in the image. The scale on the right hand side of the image 
shows the intensity with dark blue being the most intense (i.e. accounting for more 
ions) and lighter blue/white accounting for fewer ions.
The same experiment was repeated and incorporated sputter coating of gold across 
the sample surface on top of the matrix layer in an attempt to increase the sensitivity.
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The results from this analysis are presented in figure 2.7. When figures 2.6 and 2.7 
are compared it is clear that the sputter coated gold has increased the sensitivity and 
the image is much clearer. The perimeter of the tissue section can be seen along with 
the three spots of FP. The total drug amount of each spot is lpg. Although lOng 
could be detected with conventional MALDI dried droplet experiments, imaging 
experiments on the lung tissue could not be obtained at levels less than lpg; this is 
probably due to the presence of endogenous compounds that are suppressing the 
ionisation of the drug off the tissue surface.
32.5
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Figure 2.7: Direct MALDI MS Enhanced Image of Fluticasone Propionate on 
Lung Tissue. Image shows the distribution of [M+K]+ at m/z 539. The sample was 
prepared exactly as detailed for figure 2.6 where the tissue was spiked with three lpL  
spots of Fluticasone Propionate; the drug concentration of each spot was lpg. The 
matrix used was TiCb/Graphite prepared as stated in 2.2.2.1. After the matrix had 
been applied to the surface of the tissue the sample was sputter coated with gold.
The scale on the right hand side of the image shows the intensity with white being 
the most intense (i.e. accounting for more ions) and the darker colour accounting for 
fewer ions.
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2.3.3 Salmeterol
The data in figure 2.8 was obtained from conventional MALDI-MS analysis.
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Figure 2.8: MALDI Mass Spectrum of Salmeterol. MALDI mass spectrum of the 
potassium adduct of Salmeterol at m/z 454 its predominant form. The sodium adduct 
at m/z 438 and the protonated molecule at m/z 416 are also present. This spectrum 
was obtained from conventional MALDI MS analysis of the drug, Salmeterol, with 
the particle suspension matrix TiCL/Graphite.
Experiments were conducted to try to image this compound in lung tissue; however, 
results could not be obtained even at the lpg level. Possible reasons for this include 
suppression of Salmeterol ionisation by the carbon cluster peaks present in the low 
mass region under m/z 400. This drug could also not be detected from indirect 
imaging experiments.
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2.3.4 GSK256066B
GSK256066B is a compound that ionises very well in MALDI as can be seen in 
figure 2.9; the protonated, sodiated and potassiated species can be clearly seen and 
appear to suppress the matrix peaks, in particular the carbon cluster peaks. This is an 
example of analyte suppression of the matrix.
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Figure 2.9: MALDI Mass Spectrum of GSK256066B. A representative MALDI 
mass spectrum to show detection at the lpg level of GSK256066B using particle 
suspension containing graphite and TiCL from a conventional positive ion MALDI 
MS experiment.
The spectrum shown in figure 2.9 shows clearly the [M+H]+ at m/z 519, [M+Na]+ at 
m/z 541 and [M+K]+ at m/z 557.
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It appears that the protonated molecule is suppressing the matrix peaks (i.e. the peaks 
under m/z 400).
2.3.4.1 Direct Analysis of GSK256066B On Lung Tissue
Direct tissue analysis was performed in order to maintain the spatial resolution of the 
drug compound on the tissue.
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Figure 2.10: MALDI MS Image of the Distribution of [M+H]+ at m/z 519 of 
GSK256066B. Each spot represents a total drug concentration of 1 pg. The matrix 
used was TiCb/graphite. The scale on the right hand side of the image shows the 
intensity with white being the most intense (i.e. accounting for more ions) and the 
darker colour accounting for fewer ions.
The three spiked regions of drug are visible in the image; however, the intensity of 
the spot labelled number 3 in the image appears slightly more intense that the other 
two spots labelled 1 and 2 in the image. This may be due to differing levels of 
endogenous compounds and salts across the tissue surface leading to variations in 
suppression effects. In an attempt to overcome these observed suppression effects an 
indirect blotting approach was investigated.
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2.3.4.2 Indirect Blotting Analysis of GSK256066B
As this compound ionises particularly well an indirect blotting approach was used to 
try to detect drug concentrations of less than lpg off the surface of the lung tissue. 
The three drug spiked concentrations on the lung tissue were lpg, lOOng and lOng. 
The cellulose membrane was pressed against the tissue for 40 seconds which was 
considered an efficient transfer time as can be seen from the results in figure 2 . 1 1 .
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Figure 2.11: Indirect MALDI MS Image of the Distribution of [M+H]+ at m/z 
519 of GSK256066B. The cellulose blotting method was successful with the three 
spiked drug concentrations being clearly visible on the image. The scale on the right 
hand side of the image shows the intensity with white being the most intense (i.e. 
accounting for more ions) and the darker colour accounting for fewer ions.
- 7 1  -
T h is  d a ta  can  a lso  b e  re p re se n te d  as a 3D  p lo t as sh o w n  in fig u re  2 .12 .
Height (mm)' 
46.5
Intensity
100%
Width
100%
0 u>O '£=13Q.01 13 O (D
0%
Figure 2.12: 3D plot of GSK256066B MALDI MSI Data. The colour scale on the 
right hand side of the plot relates to ion intensity, with red being the most intense (i.e. 
accounting for more ions) than the blue colour. The plot corresponds to figure 2.11.
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2.4 Conclusion
The initial MALDI dried droplet experiments showed that all the drugs could be 
detected; however, drug detection directly from lung tissue is much more complex. 
This is due to the presence of endogenous compounds within the tissue which can 
interfere with the mass spectrometry analysis, for example by suppressing the 
ionisation of the drug compound and affecting/inhibiting the matrix co-crystallisation 
process. Initial experiments showed that a range of matrices were potentially 
suitable for the analysis of the four pharmaceutical compounds; however, this 
highlights the importance of matrix selection and the optimisation of the matrix on 
the tissue. For example, it was found that although a-CHCA generated good 
conventional MALDI MS data, its use was limited with the tissue imaging 
experiments. Problems were encountered as this matrix would not co-crystallise on 
the surface of the lung tissue when direct tissue experiments were conducted, a- 
CHCA was used successfully for the indirect blotting experiments.
The results show that the GSK256066B, Budesonide and Fluticasone Propionate can 
be detected in lung tissue; however, although Salmeterol can be detected with 
conventional MALDI dried droplet analysis, it cannot be detected in lung tissue. 
This is thought to be due to endogenous compounds within the lung tissue 
suppressing the ionisation of Salmeterol because Salmeterol does not appear to ionise 
as well as the other pharmaceutical compounds reported in this chapter. Suggestions 
for future work include further optimisation of methods to achieve greater sensitivity 
that will permit additional studies in analysing lung tissue dosed with drug in vivo. 
The optimisation would have to take into account the level at which the animal had 
been dosed and possible derivatisation of compounds in order to image the 
distribution. For example, studies have shown that up to 80% of administered 
Budesonide converts into Budesonide Oleate [,5] so optimisation could be achieved 
by the esterification of Budesonide into its fatty acid conjugate. If this could be 
detected it is reasonable to assume that it could be detected from animals that had 
been dosed with this drug. The dosages given to animals may vary from animal to 
animal as rats and mice are commonly used to study lung diseases. It may also vary 
depending on whom a drug is aimed at. For example, paediatric doses differ from
- 7 3 -
adult doses. Tissue blotting has shown to be an effective way to analyse the drug 
distribution as shown in figure 2.11. Whilst this did method did not work well for all 
the compounds studied it worked particularly well for GSK256066B. However, this 
compound has previously been shown to ionise very well (refer to figure 2.9).
Endogenous compounds within lung tissue also present problems that are difficult to 
overcome. The lungs could be perfused, however, this could lead to the translocation 
of compounds, and therefore any image would not reflect the true distribution. 
Tissue washing steps have been reported using graded ethanol solutions to remove 
endogenous salts from the tissue surface, thus decreasing any observed suppression 
effects. This could potentially result in the translocation of the compound or loss of 
compound if it is soluble in the washing solvent.
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Chapter 3
Analysis of Pharmaceutical Tablet 
Formulations using MALDI MSI
3.1 Introduction
Tablets are compacted pharmaceutical dosage forms that contain active ingredients 
and excipients such as bulking agents, lubricants and disintegrants. There are many 
different tablet formulations and pharmaceutical manufacturing techniques that can 
be used to produce them. The manufacturing process can vary depending on the 
chemical properties of the active pharmaceutical ingredient (API). It is of extreme 
importance to the pharmaceutical industry to evaluate the outcomes of the drug 
formulation process, and in particular for solid dosage formulations, i.e. tablets, to 
study the distribution of constituents within them. Examining the finished product is 
one way to achieve this and is vital for slow release formulations where the 
distribution of the active ingredient throughout the excipients can affect how 
effective the tablet is post-administration [1].
The introduction of the process analytical technology (PAT) initiative by the 
American Food and Drug Administration [2] has made pharmaceutical companies 
even more aware of the need to improve manufacturing efficiency and finished 
product quality [2]. Imaging techniques have formed part of this initiative and have 
already been used to investigate tablet formulations. Techniques used include 
magnetic resonance imaging (MRI) [4], Raman, Micro-Focus X-ray [1] (MFX) and 
Near Infrared (NIR) imaging [5'6]. Raman spectroscopy, in particular, has had a vital 
role in the analysis of solid pharmaceutical products owing to the minimal sample 
preparation required. APIs tend to give a good Raman response and there is less 
spectral overlap in Raman spectra than is observed with NIR. It is possible to use 
Raman spectroscopy to map APIs in pharmaceutical tablet formulations and this has 
been successfully demonstrated by Sasic C7]. However, due to the complexity of the 
data and the lack of imaging software, this can be a difficult process.
A range of mass spectrometry techniques have also been utilised in the study of 
pharmaceutical formulations. Secondary Ion Mass Spectrometry (SIMS) is a surface 
ionisation technique where secondary ions are generated by focussing a pulsed 
primary ion beam on the sample surface. The secondary ions that are generated are 
usually analysed using a Time of Flight (TOF) mass spectrometer [8]. Prestidge et al. 
have demonstrated the use of TOF SIMS for the characterisation of solid-state
- 7 8 -
pharmaceutical products [9]. SIMS can be used with imaging software to study the 
distribution of the analyte of interest within a sample.
Non-imaging techniques such as Desorption Electrospray Ionisation Mass 
Spectrometry (DESI-MS) have also been used for the analysis of pharmaceutical 
drug formulations. DESI is a technique where charged droplets created by an 
electrospray source are concentrated onto a solid sample, resulting in surface 
interaction creating secondary ions that can be detected using mass spectrometry [10]. 
DESI has been used to study pharmaceutical drug formulations [11-121 and for the 
screening of illicit Ecstasy tablets [13]. Whilst DESI requires no sample preparation, 
it is relatively fast and is a soft ionisation technique, but at present there is no 
commercial imaging software available for this application. Therefore only profiles 
(i.e. surface mass spectra) can be obtained. It should be noted, however, that quite 
often profiling experiments provide the user with enough information regarding the 
sample of interest.
MALDI MS has been applied previously to the analysis of clandestine tablets [14], 
where the tablets were ground into a fine powder and dissolved in methanol in order 
to permit spot target analysis to be performed using a combination of a-CHCA and 
cetrimonium bromide (CTAB) in a water:acetonitrile solution (50:50 v/v).
The work presented in this chapter demonstrates the first use of MALDI MSI to 
study tablets. The overall aim of this work was to map the distribution of the active 
drug throughout all the excipients contained within the tablets. MALDI-MSI has 
been assessed as a potential technique to directly image the distribution of the active 
drug throughout the tablet and to also provide some quantitative information in 
relation to the manufactured dose of the tablet.
The following tablets were obtained for MALDI MSI analysis: a confidential tablet 
formulation, tablet X (placebo, lmg, 3mg and 6mg dosage forms); Sildenafil citrate 
(Viagra 25mg); Paracetamol (500mg); Aspirin (75mg); Anadin Extra (a mixture of 
aspirin (300mg), Paracetamol (200mg) and Caffeine (45mg), and Solpadeine (a 
mixture of Paracetamol (500mg) and Caffeine (65mg).
Principal Component Analysis (PCA) software is used to simplify multidimensional 
datasets. PCA has been previously incorporated into the interpretation of MALDI 
MSI data to discriminate between different regions in mammalian tissue sections tl5‘
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17] and to evaluate data from the analysis of porcine skin that had been treated with 
hydrocortisone [I8]. In this chapter it is demonstrated how PCA can be used to 
differentiate between the active component and the excipients contained within the 
tablet.
3.2 Experimental 
3.2.1 Materials
a-cyano-4-hydroxycinnamic acid (a-CHCA), ethanol (EtOH, HPLC grade) and 
trifluoroacetic acid (TFA, HPLC grade) were purchased from Sigma Aldrich, Dorset, 
UK. The following tablets were purchased commercially from a local pharmacy: 
Paracetamol 500mg (Wallis Laboratory Limited, Bedfordshire, UK), Aspirin 75mg 
(M & A Pharmachem Ltd, Greater Manchester, UK), Anadin Extra (Wyeth 
Consumer Healthcare, Berkshire, UK) and Solpadeine (Glaxosmithkline Dungarvan 
Ltd, Co Waterford Ireland). Sildenafil citrate (Viagra) 25 mg dosage form and Tablet 
X in placebo, lmg, 3mg and 6mg dosage forms were supplied by Pfizer, Kent, UK. 
The tablet cutter used was purchased commercially, PillCutter, PillMate®, Shantys 
Ltd, Essex, UK.
3.2.2 Sample Preparation Methods
3.2.2.1 Preparation of Tablets for Conventional MALDI Dried Droplet 
Experiments
In order to asses the suitability of a range of matrices for the analysis of 
pharmaceutical tablet formulations, different tablets were dissolved in 2mL of 
ethanol and sonicated for approximately 15 minutes. lpL of drug solution was 
combined with lpL of matrix and spotted onto a stainless steel MALDI target plate. 
It was found that a-CHCA was the best choice of matrix for these studies as the 
drugs ionise well with this matrix.
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3.2.2.2 Preliminary Studies into Tablet Preparation for MALDI MSI
Tablets are manufactured in many different shapes and sizes and therefore there is a 
requirement to optimise the sample preparation procedure for each tablet as this 
ultimately affects the data generated and image quality. The preliminary studies 
began with tablet X; a series of small tablets with convex surfaces. The underside of 
the tablet was filed using an emery board as a flat surface was required for the 
mounting of the tablet section onto the recessed MALDI target plate; this was 
followed by matrix application (a-CHCA 25mg/mL in EtOH containing 0.1% TFA) 
applied using an airspray deposition method. The results in section 3.4.1 
demonstrate the problems encountered with this sample preparation method. In 
order for improved MALDI MSI analysis on tablets to be performed the sample 
preparation method was optimised further (refer to section 3.4.2).
Tablet fractured horizontally 
using commercially available 
tablet cutter
Figure 3.1: The Curved Surface of Tablet X. Photograph of tablet X showing the 
curved surface of the tablet and the position at which the horizontal section was 
obtained using a commercially available tablet cutter.
Curved tablet surface
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3.2.2.2.1 Optimisation of the Tablet Preparation Procedure
Tablet sections approximately 1mm in thickness were created using a tablet cutter to 
fracture the tablet, thus exposing the surface of the tablet. (Note, this procedure was 
not necessary for the Paracetamol and aspirin tablets as they already had flat 
surfaces). The underside of the tablet was filed down in order to ensure that it would 
fit into a recessed MALDI target plate.
3.2.2.3 Matrix Selection and Application
Preliminary experiments were conducted to assess the suitability of different 
matrices and solvents. Compound X and the other tablets studied in this chapter 
were soluble in ethanol and ionised efficiently using a-CHCA dissolved in ethanol 
containing 0.1 % TFA.
The matrix was applied using an airbrush that required manual operation. Important 
parameters to control include the amount of matrix that is applied to the sample and 
wetting of the sample caused by applying the matrix too quickly should be avoided. 
Sample wetting can be avoided by optimising the distance between the airbrush and 
the sample, the pressure at which the matrix is applied and choosing a suitable 
solvent such as acetone or ethanol that evaporates very quickly. Approximately 
1.5mL of matrix was applied to each tablet at a spray distance of about 10 inches 
away from the sample surface.
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Figure 3.2: The Flat Surface of Tablet X. A photograph showing the flat surface of 
the tablet section obtained with the optimised sample preparation method and affixed 
to the MALDI target plate.
3.3 Instrumentation
3.3.1 Mass Spectrometric Analysis
All analyses were performed in positive ion mode on an Applied Biosystems/MDS 
Sciex hybrid quadrupole time-of-flight mass spectrometer (Q-Star Pulsar-/) with an 
orthogonal MALDI ion source and a high repetition Nd: YAG laser (1 kHz). The 
Nd: YAG laser has an elliptical spot size of 100x150pm. The laser scanned over the 
sample in a raster pattern and acquired data at 100pm increments. The laser fired at 
a power of 30% (3.2pJ) at each location for 2 seconds.
3.3.2 Visualisation Software
oMALDI server software version 5 (Applied Biosystems/MDS Sciex) was used to 
generate images from the acquired mass spectral data.
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3.3.3 Principal Component Analysis (PCA)
PCA was performed using the "Markerview" software package (Applied 
Biosystems/MDS Sciex). Five random locations from the tablet image data were 
taken and these data were entered this data into Markerview. Supervised PCA was 
performed using Pareto scaling. This type of scaling calculates the square root of the 
standard deviation and uses this information as a scaling factor [19]. This in turn 
reduces any major intensity changes that are sometimes observed within the sample 
and also with the matrix peaks.
3.4 Results and Discussion
3.4.1 Preliminary Tablet X Data Prior to Optimisation of Sample 
Preparation
There are many tablets that are commercially available that have a convex tablet 
surface.
It was found that one of the most important aspects of the sample preparation 
procedure was to produce a flat surface. The image presented in Figure 3.3 
demonstrates the importance of the sample preparation procedure. As can be seen 
there is a doughnut effect in which it appears that the highest concentration of 
compound X is around the edges of the tablet with less drug in the middle of the 
tablet. This is hypothesised to be a laser-induced effect resulting in the distortion of 
the image; the laser may be too close to the centre of the tablet due to its convex 
nature and too far away from the edges as explained diagrammatically in figure 3.4.
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Figure 3.3: MALDI MS Image of Tablet X. Tablet X (3mg) with a convex surface 
exposed for MALDI MSI analysis. The scale on the right hand side of the image 
shows the ion intensity with the dark blue colour being the most intense (i.e. 
accounting for more ions) and the lighter blue/white colour accounting for fewer ions.
Nd: YAG Laser
Figure 3.4: Schematic Diagram of Proposed Laser Position. A proposed
schematic diagram to explain the image distortion by way of laser position: (a) shows 
how the laser may be too close to the curved tablet surface and too far away from the 
edges of the tablet; (b) shows that the laser is consistently at the same distance to the 
tablet section surface; the edge of the tablet where the laser misses could explain the 
'flattening' effect observed in some of the tablet images.
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3.4.2 Tablet X (placebo, lmg, 3mg and 6mg tablets) Post-Optimisation 
of Sample Preparation Method
Figure 3.5 is a collection of representative spectra for the analysis of Tablet X: (a) 
placebo; (b) lmg tablet; (c) 3mg tablet and (d) 6 mg tablet. In figure 3.5 b-d the 
protonated molecule ([M+H]+ = m/z 507) of the active drug is clearly visible. The 
full scan spectra show a relative increase in ion counts when the concentration of the 
active increases. The ion counts for the matrix peaks decrease as the ion intensity for 
the active compound increases. With higher concentrations of this particular drug it 
is observed that the matrix peaks are suppressed. This is because the active drug in 
this case ionises very well. Figure 3.6 shows the corresponding images showing the 
distribution of m/z 507 throughout the tablet sections. These have been normalised 
against the corresponding matrix peak ([M+H]+ at m/z 190). The intensity scale on 
each of the images represents ion intensity/abundance for m/z 507; thus the deeper 
the colour, the more of the active pharmaceutical ingredient there is in that particular 
location.
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Figure 3.5: MALDI Mass Spectra of the Different Tablet X Concentrations. Full
scan spectra for placebo (a), lmg tablet (b), 3mg tablet (c) and 6 mg tablet (d). The 
matrix peaks are clearly visible on the placebo spectrum; however, as the compound X 
(m/z 507.16) concentration increases suppression of the matrix peaks is observed.
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Figure 3.6: MALDI MS Images of Tablet X at a Range of Drug Concentrations.
Images show the protonated molecule (m/z 507.16) normalised against the 
corresponding protonated matrix peak (m/z 190.05). The images show that the 
active component (compound x) is relatively homogenously distributed throughout 
the tablet at different concentrations a) lmg, b) 3mg and c) 6 mg. The scale on the 
right hand side of the image shows the ion intensity with the dark blue colour being 
the most intense (i.e. accounting for more ions) and the lighter blue/white colour 
accounting for fewer ions.
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3.4.2.1 Quantitative Aspects of Tablet X Analysis
MALDI MSI can provide quantitative information. Five spectra obtained from each 
imaging run were randomly selected and a plot of the intensities of m/z 507/190 is 
shown in figure 3.7.
PCA analysis was performed to discriminate between the tablets containing 
compound X and the placebo and between the different concentrations of compound 
X in the tablets. PCA was used to explore how the four tablets (placebo, lmg, 3mg 
and 6mg) differ in composition statistically. Figure 3.8 shows the results from the 
PCA analysis and shows the following information:
• The scores plot shows significant grouping for the three different dose tablets 
and a separate grouping for the placebo.
• The corresponding loadings plot confirms that the more active ingredient the 
tablet contains, the more it groups towards m/z 507. As the placebo doesn't 
contain any active compound, it groups furthest away from m/z 507.
The matrix peaks were not excluded from this analysis, in order to illustrate further 
that when the tablets contain a readily ionisable active compound, it suppresses the 
matrix signal. As the placebo does not contain a component that is readily ionisable 
the matrix peaks suppress the excipient peaks. Therefore, it is an interesting 
observation that although one would expect the grouping for the placebo to be 
furthest away from the m/z 507 ion from the active compound; this is also where the 
matrix peaks are located in the loadings plot (m/z 146.05, m/z 172.03, m/z 190.05, 
m/z 212.03). PCA supports the quantitative aspect of this investigation and it may 
also provide information on matrix suppression.
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Figure 3.7: Graph of Increasing Tablet X Concentrations. A graph to show the 
normalised increase in intensity observed as the concentration of the active 
pharmaceutical ingredient was increased in the tablet formulations. Five spectra 
were randomly selected and the mean value was plotted. The error bars represent the 
standard deviation. The correlation coefficient, R2, was computed using Excel 2003. 
The range for R2 values is between 0 and 1 where 0 represents no statistical 
correlation and 1 is the highest achievable correlation. The R2 value of 0.9963 shows 
that there is a statistical correlation between the normalised intensity on the y axis 
and tablet concentration on the x axis.
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Figure 3.8: PCA Analysis of Tablet X. The same five spectra used to produce the 
graph in figure 3.7 were entered into the Markerview software and supervised PCA 
analysis was performed using Pareto scaling. There is clear separation between the 
placebo and the tablets containing the active component compound X. The tablets 
containing the active drug are grouped closely together as can be seen in the scores 
plot and group according to their drug concentration.
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3.4.3 Sildenafil Citrate (Viagra 25mg)
Sildenafil citrate (Viagra) is a drug developed by Pfizer, used to treat erectile 
dysfunction and pulmonary arterial hypertension.
The distribution of m/z 475 (the Sildenafil base [M+H]+) throughout a section of a 
Viagra tablet can be seen in figure 3.10. The image data has been normalised against 
the corresponding matrix peak ([M+H]+ at m/z 190). The full scan spectrum shows 
that the sildenafil base dominates the spectrum suppressing the ions associated with 
the matrix. The sodium adduct is also present at m/z 497.
Figure 3.9: The Chemical Structure of Sildenafil base.
IUPAC Name: 5-(2-ethoxy-5-((4-methylpiperazin-l-yl)sulfonyl)phenyl)-l-methyl- 
3 -propyl-1 H-pyrazolo [4,3 -d] pyrimidin-7-one 
Formula: C22H30N6O4S 
RMM: 474.20
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Figure 3.10: MALDI MS Image of Sildenafil. The distribution of [M+H]+ at 
m/z 475 normalised against the corresponding matrix peak at m/z 190. The scale on 
the right hand side of the image shows the ion intensity with the dark blue colour 
being the most intense (i.e. accounting for more ions) and the lighter blue/white 
colour accounting for fewer ions.
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Figure 3.11: MALDI Mass Spectrum of Sildenafil. The full scan mass spectrum 
of Sildenafil showing the protonated molecule at m/z 475.
- 9 3 -
3.4.4 Paracetamol (500mg) and Aspirin (75mg)
Images have been obtained for aspirin (acetylsalicylic acid) and paracetamol 
(acetaminophen) -  both drugs have analgesic and antipyretic properties; however, 
aspirin also acts as an anti inflammatory.
Figure 3.13 shows the distribution of the [M+H]+ of Paracetamol at m/z 152 
throughout a tablet section. These data have been normalised against the 
corresponding matrix peak ([M+H]+ = m/z 190). The image and the corresponding 
ion intensity scale show that the distribution of Paracetamol is consistent and appears 
relatively homogenous throughout the section, although the edges of the tablet seem 
to be brighter indicating a higher concentration of Paracetamol towards the outer 
edges of the tablet. This is thought to arise through laser focussing effects as 
discussed in section 3.4.1.
Figure 3.16 shows the distribution of the aspirin sodium adduct ion ([M+Na]+= m/z 
203) throughout a tablet section. These data have been normalised against the 
corresponding matrix peak ([M+Na]+ = m/z 212). The sodium adduct ion was 
imaged rather than the lower intensity protonated molecule ([M+H]+ = m/z 181). The 
image shows that the aspirin appears to be located on the outer parts of the tablet as 
the ion counts for the middle part of the tablet section suggest that there is less 
aspirin in the middle. The high concentration of active ingredient at the tablet 
surface may be due to greater compression at the surface. This may cause an increase 
in density at the surface when the tablet is pressed. Increased tablet density would 
increase the spatial concentration of the API without increasing its actual 
concentration.
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3.4.4.1 Paracetamol
Figure 3.12: The Chemical Structure of Paracetamol. 
IUPAC Name: N-(4-hydroxyphenyl) acetamide. 
Formula: C8H9NO2 
RMM: 151.06
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Figure 3.13: MALDI MS Image of Paracetamol. The distribution of [M+H]+ at 
m/z 152 normalised against the corresponding protonated matrix peak at m/z 190. 
The scale on the right hand side of the image shows the ion intensity with the dark 
blue colour being the most intense (i.e. accounting for more ions) and the lighter 
blue/white colour accounting for fewer ions.
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Figure 3.14: MALDI Mass Spectrum of Paracetamol. The full scan MALDI mass 
spectrum for paracetamol tablet analysis showing the protonated molecule at m/z 
152.
3.4.4.2 Aspirin
O ^ /O H
Figure 3.15: The Chemical Structure of Aspirin. 
IUPAC Name: 2-acetoxybenzoic acid.
Formula: C9H80 4 
RMM: 180.04
- 9 6 -
Figure 3.16: MALDI-MS Image of Aspirin. The ion distribution image of m/z 203
normalised against the corresponding matrix ion at m/z 212. The scale on the right 
hand side of the image shows the ion intensity with the dark blue colour being the 
most intense (i.e. accounting for more ions) and the lighter blue/white colour 
accounting for fewer ions.
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Figure 3.17: MALDI Mass Spectrum of Aspirin. A representative MALDI mass 
spectrum of Aspirin showing the [M+Na]+ at m/z 203.
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3.4.5 Solpadeine and Anadin Extra
Many over the counter pain relief drugs such as Anadin Extra contain a mixture of 
paracetamol and aspirin and some of these drugs, for example Solpadeine, contain 
caffeine to accelerate pain relief. Conventional MALDI MS analysis has been 
applied to Anadin Extra and Solpadeine in an attempt to detect the different drugs 
contained within each tablet as it was not possible to obtain images for Solpadeine 
and Anadin Extra. This was due to the consistency of the tablet; the crumbly 
textures of these tablets don't make them amenable to the sectioning process.
3.4.5.1 Solpadeine
174 05
[M+Na]+ Paracetamol (m/z 174)
[M+H]+Paracetamol (m/z 152)
[M+H]+Caffeine (m/z 195)
> T  234 01
341.1 L*
530.
01206
. 3;
m /z,
Figure 3.18: MALDI Mass Spectrum of Solpadeine. The protonated Paracetamol 
can be seen at m/z 152, the sodiated Paracetamol peak dominates the spectrum and 
the protonated caffeine can be seen at m/z 195.
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The Spectrum in figure 3.18 shows the presence of both the protonated and sodiated 
paracetamol at m/z 152 and m/z 174 respectively. Caffeine was also detected as a 
protonated molecule at m/z 195. The protonated and sodiated paracetamol (500mg) 
compared to the quantity of caffeine contained within the tablet (65mg).
3.4.5.2 Anadin Extra
[M+H]+ Caffeine (m/z 195)
[M+H]+ Paracetamol (m/z 152)
[M+Na]+ Aspirin (m/z 203)
cc
^439.0430 i.i: 579 968.18
m /z,
Figure 3.19: MALDI Mass Spectrum of Anadin Extra. The protonated 
Paracetamol can be seen at m/z 152, the protonated Caffeine at m/z 195 dominates 
the spectrum and the sodiated Aspirin can be seen at m/z 203.
All the pharmaceutical components (caffeine, paracetamol and aspirin) of Anadin 
Extra were detected by conventional MALDI analysis as shown in figure 3.19. The 
ion from sodiated caffeine was the most prominent peak in the MALDI mass 
spectrum although this was the least abundant drug in the tablet, containing only 
45mg.
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3.5 Conclusion
A novel approach utilising MALDI MSI for the direct analysis of tablets has been 
demonstrated in this study. The sensitivity, specificity and rapid analysis time, 
together with the imaging capabilities make MALDI MSI a valuable technique in 
many biomedical disciplines. The introduction of MALDI MSI has been invaluable 
in pharmaceutical analysis both in animal models of drug distribution and in solid 
pharmaceutical formulations. In this chapter, the importance of being able to 
visualise the spatial localisation of a compound of interest within a sample, in this 
case tablet formulations, has been evaluated. Images have been obtained for Tablet 
X, Viagra, Paracetamol and Aspirin. However, the crumbly nature of Solpadeine 
and Anadin Extra made it very difficult to obtain tablet sections of ~lmm in 
thickness and therefore images could not be obtained for these tablets. The shape of 
the tablet can dictate the sample preparation to some extent. For example, if a tablet 
had a convex surface this would need to be sectioned in a way that would produce a 
relatively flat surface - this was required in order to perform MALDI analysis on the 
Tablet X dosage forms.
The tablet images in figure 3.6 appear to have relatively homogenous distributions of 
the active compound throughout the excipients. However, the top of the tablet 
images (most apparent in figure 3.13) initially appear to have a higher concentration 
of active compound. The charging effect has been reported when the ionization 
sources are of axial configuration [20]. This can be overcome by sputter coating the 
sample with a metal over the layer of the matrix [21]. The non-conductive nature of 
tablet sections of ~lmm thickness could potentially be due to a charging effect. 
However, this is unlikely as the kinetic energy of the ions is decoupled from the mass 
analyzer in orthogonal QqTOF instrumentation. A more likely explanation is that the 
angle of the laser is such that it is firing at the outer edge of the tablet and not at the 
surface; this is predominantly observed at the top of the tablet sections. Future 
studies could include re-adjustment of the laser to try to combat such a problem.
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Chapter 4
Metabolite Profiling of Wheat Grain using 
IR LDI MS and UV MALDI MSI
4.1 Introduction to Plant Metabolomics
Metabolomics is a rapidly expanding area of scientific research and metabolomics- 
based studies have been applied to many areas of science; examples include studying 
the effects of genetic manipulation [1], the investigation of diseases such as cancer t2] 
and diabetes [3], drug discovery [4] and toxicology [5], amongst others. In this chapter, 
a metabolomics strategy has been used to investigate plant tissue using MALDI MS 
for the imaging and profiling of developing wheat grains. In recent years, there has 
been a surge in plant metabolomic studies [6] ranging from investigations into 
secondary metabolism [7] to gaining a greater understanding of the changes in 
metabolite levels during abiotic stress [6,8]. Plant metabolomic analyses have been 
previously performed predominantly on fruits [9,10], leaves [11] and tubers [12].
4.1.1 Clarification of Terminology
The terms metabolomics and metabonomics are often used interchangeably to mean 
the study and characterisation of metabolites, usually small molecule metabolites, in 
biological systems [13].
The standard definitions that have been established are as follows:
Metabolites: the intermediates of biochemical reactions within cells that are 
responsible for connecting many pathways providing information on the cellular 
status of the cell or tissue, thus defining the phenotype of the cell or tissue in 
response to genetic or environmental changes [14]. Metabolites are compounds that 
are formed by metabolic processes therefore providing information that complements 
genomics, transcriptomics and proteomics in relation to gene expression, protein 
expression and enzyme activity [14].
Metabolome: The identification and quantification of all the intracellular 
(endometabolome) and extracellular metabolites (exometabolome) that have a 
molecular mass under lOOODa [15].
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Metabolomics: A term used to describe the identification and/or quantification of 
metabolites contained within cells and tissues tl6].
Metabolomics generally utilises chromatographic-mass spectrometry-based 
techniques to generate data. The approaches and methods are now very similar 
between metabonomics and metabolomics; however, the term metabonomics often 
relates more to the analysis of biofluids in biomarker discovery, whereas 
metabolomics is applied more to tissue analysis, biomarker discovery and gene 
function analysis [14].
Metabonomics: “the comprehensive and simultaneous systematic profiling of
multiple metabolite levels and their systematic and temporal changes caused by 
factors such as diet, lifestyle, environmental, genetic effects, pharmaceutical effects 
both beneficial and adverse in whole organisms”[16].
Metabolite Profiling: This approach can encompass either metabonomics or
metabolomics and is generally the term given to the detection, identification and/or 
the quantitation of metabolites in a sample [14].
4.2 The Importance of Plant Metabolomics
Around 20 plant species provide approximately 90% of the world’s supply of food: 
some of the major crops include rice, wheat, barley, potato and soy [17]. In addition 
to their significant role as food crops, plants and plant material yield numerous 
products of importance to human sustenance, including wood, vitamins and 
medicinal drugs with 80% of all medicinal drugs originating from plant material. It 
is thought that these drugs have been derived from only 2% of the world's entire 
plant species [17]. Therefore, it is plausible that metabolomics may have a major role 
in the detection and identification of potential therapeutic agents and significant drug 
discovery.
As plants are autotrophic organisms there are features that are unique to plant 
metabolomics such as the photosynthetic process where light is used as the energy
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source and adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide 
(NADH) are used in the synthesis of glucose by carbon dioxide [17].
The metabolism of plants is largely dependent on the amount of light available; 
however, carbon availability can also have an impact on the metabolic profile [18]. 
Metabolomics is also of great importance in the investigation of genetically modified 
(GM) crops and in the elucidation of the genetic modification process; thus 
metabolomics-based studies are particularly useful to make comparisons between 
GM crops and non-GM crops for the assessment of crop quality and nutritional value
[ 19]
4.2.1 Plant Metabolism
Metabolism can be separated into primary metabolism and secondary metabolism. 
Primary metabolites include compounds that are essential to life such as amino acids 
and sugars. Secondary metabolites are formed by pathways derived from primary 
metabolism and are characterized by their chemical diversity and often their 
unknown function, although it is thought they operate in signalling cascades [20].
Due to the dynamic nature of metabolism it is important to ensure that metabolism 
has been stopped before metabolomic experiments are conducted; this can be 
achieved by quenching of the sample.
4.2.2 Quenching of Plant Tissue
Quenching refers to the process whereby metabolism is stopped [21]. This process 
can vary for different biological samples. Once the tissue has been harvested 
metabolism must be stopped immediately in order to preserve the metabolic status of 
the sample. The quenching of plant tissues is generally done using liquid nitrogen as 
this method enables rapid freezing of the sample; samples can then be stored at - 
80°C prior to analysis as this is thought to preserve sample integrity. Other 
quenching agents include ice cold methanol or acidic treatments [2IJ. However, with 
this method of quenching the sample is not frozen. Therefore, if metabolite
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localisation experiments are to be conducted, the use of such solutions could result in 
metabolite delocalisation, thus interfering with analysis.
Once the plant tissue samples have been quenched the tissue can be stored at -80 °C 
or alternatively it can be freeze dried. As many metabolomics approaches utilise an 
extraction step, sample thawing must be avoided or limited in order to ensure that the 
metabolic status of the sample does not change. Freeze drying is an alternative 
method of plant tissue storage that preserves the metabolic status of the tissue as 
enzyme activity cannot occur without the presence of water [22]. However, it has 
been reported that the freeze drying process can decrease metabolite extraction 
efficiency due to a potential irreversible problem that may occur where the 
metabolites adhere to the cell walls and membranes [23].
4.2.3 The Chemical Complexity of Metabolomics
Metabolomics is a dynamic process whereby the metabolites produced by enzyme- 
catalysed reactions in cells have a finite half life as they are constantly being 
produced, transformed into other compounds or degraded [17]. These reactions are 
organised into metabolic pathways that depict the cyclic nature of metabolism. 
These pathways also show how metabolites can undergo modification reactions in 
order to serve as a precursor that can be converted into a biologically active 
compound. The metabolic pathway databases are discussed in more detail in section 
4.4.
Type of Modification Chemical Addition
Hydroxylation OH
Phosphorylation P 0 4
Reduction h 2
Amidation n h 2
Acetylation c h 3c o
Table 4.1: Common Metabolite Modifications [ 17].
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Metabolites often retain the chemical characteristics of their parent metabolite but 
they can also form larger chemical compounds. An example of this is the conversion 
of glucose into storage carbohydrates such as starch [17]. Metabolites may also be 
converted into smaller compounds; this can occur through oxidation reactions that 
lead to the loss of water molecules. The synthesis of metabolites is crucial for cell 
survival as often the metabolites produced have pivotal roles in contributing to the 
infrastructure of the cell and/or have an energy-related role. Terminology has been 
developed to summarise these processes; anabolic metabolism is the synthesis of 
complex molecules for energy storage and catabolism is the degradation of complex 
molecules for energy release [24].
There are many factors that can cause variability in metabolic profiles. For example, 
environmental factors can influence the concentrations of metabolites observed [25].
4.3 Techniques Used to Study Metabonomics/Metabolomics
There are many techniques that can be employed to investigate the metabolome. The 
most widely used techniques include Nuclear Magnetic Resonance (NMR) 
spectroscopy1261 and hyphenated mass spectrometry techniques such as Liquid 
Chromatography-Mass Spectrometry (LC-MS) [2?1 and Gas Chromatography Mass 
Spectrometry (GC-MS)[28]. NMR is a fast technique and there are no separation 
steps prior to analysis. The major disadvantage of this technique is the dynamic 
range over which it operates along with its poor sensitivity.
One of the main problems associated with the use of GC-MS is the need for chemical 
derivatisation to make the metabolites more volatile[29].
4.3.1 The Role of Mass Spectrometry in Metabolomic Research
Mass Spectrometry based techniques have become increasingly important in the area 
of metabolomics. Numerous metabolomics approaches utilise a chromatographic 
separation technique coupled to a mass spectrometer - the combination of 
chromatography with spectrometry provides good sensitivity and selectivity [30].
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The most influential aspects of MS analyses for metabolomic studies are:
• High sensitivity
• High throughput
• Identification of compounds from complex biological samples
• Information relating to metabolite structure can be obtained by 
fragmentation (MS/MS)
• Quantitative information can be obtained
The two most common hyphenated MS techniques that are used in this area of 
science are GC-MS [28) and LC-MS [27]. GC-MS has been used to profile plant 
functional genomics; however, whilst this technique is sensitive it requires time- 
consuming sample preparation steps, for example the extraction and derivatisation of 
analytes. GC-MS does not produce rapid results and some particular classes of 
compounds, for example non-volatile, polar macromolecules cannot be analysed 
using this technique. At present, LC-MS, in particular LC/ESI-MS, is probably the 
most widely used technique for metabolite studies. This is because it can detect a 
range of masses, is reproducible and sensitive, is a soft ionization technique and only 
requires very basic sample preparation compared with GC-MS [31]. Both GC-MS and 
LC-MS require an extraction process. This is usually done using liquid extraction 
where the solvent that is selected is dependent upon the metabolites to be extracted 
and the analytical technique that is to be used. Thus, the major drawback to 
extraction-related sample preparation is that it is difficult to locate spatially within 
the biological sample where the metabolites originated from.
The interpretation of metabolomics data can be rather challenging because a given 
metabolite may participate in a myriad of biochemical pathways. Due to the 
complex nature of cell metabolism it is extremely difficult to observe a direct link 
between metabolomics and genomics.
Metabolites are extremely chemically diverse, both in structure and in their 
properties such as their polarities, modifications that they may undergo (refer to table 
4.1) and the isomeric forms in which they can present themselves. These factors can 
further complicate analyses for many analytical techniques [,7].
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A metabolomics technique is desired that can measure, in parallel, many different 
metabolites in one experiment, can provide reproducible data, is relatively fast in 
performing analyses and can be automated [32] -  Matrix -Assisted Laser Desorption 
Ionisation Mass Spectrometry Imaging (MALDI MSI) fits all the criteria.
One of the major advantages in using MALDI MSI for metabolomic applications is 
that this technique boasts good sensitivity. Not only can this technique detect a 
compound, it also allows for the visualisation of where analytes of interest are 
spatially located in the tissue section. The spatial resolution of metabolites in 
complex biological tissues, such as plant tissue, can provide useful information that 
may be pivotal to the understanding of metabolic processes. There is increasing 
interest in the use of MALDI MSI for plant science applications -  agrochemicals 
(Mesotrione and Azoxystrobin) have been investigated in soya plants [33]. The use of 
MALDI MSI to investigate the oligosaccharide distribution in wheat stems has been 
reported and it was commented that the sensitivity achieved was comparable with 
what had been achieved in their previous studies carried out using LC-MS [34].
More recently MALDI MS has been applied to the study of temperature-induced 
stress in wheat[35].
4.4 Metabolomic Databases
Once data has been generated there are many databases available for the tentative 
identification of the unknowns. Metabolomic databases often contain information on 
compounds ranging from many different organisms to drug metabolism pathways. 
These databases demonstrate the extensive work by laboratories and consortia 
around the world in identifying unknown metabolites and establishing accurate 
databases that can contain thousands of metabolites. However, there is a lack of 
complete metabolomic databases. Section 4.4.1 details some of the most established 
databases.
- 110-
4.4.1 Spectral Databases
Metlin: This database was a collaborative effort between the Siuzdak and Abagyan 
research groups at the Scripps Research Institute, La Jolla, USA. Searches can be 
performed using pre-corrected neutral masses or searched for the loss or gain of a 
proton; it does not correct for sodiated and or potassiated ions [36].
MassTRIX: MassTRIX is a metabololite search facility that uses the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathways. Masses with their 
corresponding identities are entered in text format and are matched up with possible 
metabolites in the Kegg pathway. Mass correction can be performed for the loss or 
gain of a proton and for sodium adducts. Alternatively neutral masses can be 
searched for mass corrected data. Specific organisms can be searched by entering 
the organism of interest before the search is performed [37].
4.4.2 Metabolic Pathway Databases
Metabolic pathway databases contain information based on the information obtained 
from experimental literature where the biochemical reactions are organised into 
maps/pathways.
Kyoto Encyclopedia of Genes and Genomes (KEGG): contains in excess of 15 
000 compounds from a range of plants, animals and bacteria, 8872 drugs and 
approximately 11 000 glycan structures. Approximately 93, 000 pathways have been 
established from 336 reference pathways and are detailed for over 700 organisms. A  
recent addition to the KEGG database is KEGG Plant containing information relating 
to plant biosynthetic pathways and phytochemical compounds. The KEGG database 
is divided into sections that are focussed on a particular area thus making it easier to 
navigate [38].
MetaCyc: A database that contains over 1200 pathways from more than 1600 
organisms that encompasses the pathways of both microorganisms and plants [39].
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Metacrop: A database that also contains metabolic pathway information; however, 
as its name suggest it is more tailored for the analysis of crop plants. It contains 
information for 6 major crop plants, one of which is wheat and their related 
biochemical pathways [40,41].
4.5 A pplications o f Plant M etabolom ics
The first significant plant related publication was by Sauter et al. in 1991 f42] using 
GC-MS to investigate the effects of herbicides on barley plants.
In recent years, metabolomics has been applied to many different areas of science. 
These include plant biochemistry, testing crop quality and many more [43]. 
Environmental induced stress has been investigated previously in plant material, for 
example to study the effects of temperature on Aradopsis thaliana |42, 441. Another 
example has been presented where the plant stress was in the form of a deficiency in 
available nutrients [45].
The integration of all the information obtained in the 'omics sciences is known as 
systems biology (refer to figure 4.1); however, sophisticated mathematical models 
are required for the systems biology approach due to the complexity of the data. For 
example, small changes in the proteome can have a significant impact on the 
metabolome as enzyme activity is required for many metabolic processes [46]. 
Metabolomics therefore represents the final stage of systems biology with 
metabolites representing the end products of gene expression and which can provide 
complementary information in relation to other 'omics sciences [44].
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Figure 4.1: Schematic Diagram of the Interactions in the 'Omics': The
schematic shows the progression from genomics-based studies to the metabolomic 
level with metabolites being the end products of gene expression, adapted from [47].
4.5.1 Phenotyping Plant Samples
Metabolomic studies can be very useful for phenotyping experiments, for example 
phenotyping genetically engineered plants [48]. Metabolomics could also be applied 
to the study of plants that have been subjected to different environmental conditions, 
as these changes, whether they are genetic or environmental, will have an impact on 
the observed metabolic profile. Published results show that starch biosynthesis can 
be studied in transgenic potato tubers in this way f48].
A comparison has also been made between organic and non-organic crops by 
investigating the metabolic differences observed f49].
4.6 Limitations of Metabolomics
There has been a movement in recent years to perform non-targeted metabolite 
studies where an attempt to detect as many metabolites as possible within a sample is 
performed using a technique such as GC-MS [50]. However, such experiments lead to 
an abundance of peaks within the mass spectrum generated. It has been estimated 
that up to 70% of all the detected masses using GC-MS are unknown compounds and 
that they will remain unknown until metabolomics databases are improved [17].
There are also currently many problems associated with the use of metabolomics 
databases. These include databases that contain non-biological compounds that have 
been established for the existing techniques such as NMR and GC-MS. There are 
limited database resources for the data generated by MALDI as many databases do 
not take into account the sodiated and potassiated compounds commonly observed 
with this technique in both plant and animal tissues due to the presence of 
endogenous salts. Mass correction is therefore a pre-requisite before the data can be 
entered into the relevant database. Another method of identifying unknown 
compounds is to obtain standards; however, the main problem associated with this 
method of compound identification is that many plant metabolites especially those 
that fall into the secondary metabolite category are not commercially available [9]. At 
present, the analytical technique that seems the most appropriate taking these two 
limitations into account is the coupling of LC-MS with NMR due to the achievable 
high throughput analysis together with chemical selectivity and structure elucidation
[51]
4.7 MALDI MS Analysis of Wheat Grain
The increasing demand for high throughput analysis in drug discovery and 
bioanalysis, where the samples are often complex mixtures that contain contaminants 
such as salts and buffers, has led researchers to re-evaluate MALDI MS for small 
molecule analysis [52].
This chapter details the use of UV MALDI MSI and IR LDI MS for the imaging and 
profiling of plant tissue where wheat grain has been used as the model system. In
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particular, a number of different matrix types have been studied and the use of IR 
LDI MS has been investigated as a matrix-free option
The aim of the work presented in this chapter was to develop methodology for the 
high-throughput metabolomic analysis of plant samples using wheat grain as the 
model system. The approach used was non-targeted i.e the method was not 
optimised to study specific metabolic pathways but to simultaneously detect as many 
metabolites as possible.
4.7.1 W heat
The developmental stage of the wheat grain is important as this can affect the 
metabolic profile; therefore it is important to harvest the crop at similar 
developmental stages. In wheat this is usually defined by the days post-anthesis. 
Wheat is a cereal crop that is grown worldwide and on a global scale is one of the 
most important food grains for human consumption. Therefore, it is of great interest 
to study which endogenous metabolites wheat grains are comprised of and what 
makes wheat such a nutritionally important crop. Wheat has a large genome 
comprising of 16 000Mb; this is in the magnitude of 40 times larger than the rice 
genome [53]. Poor weather conditions and a movement towards growing 'greener' 
biofuel crops in place of wheat have previously led to worldwide shortages. 
Therefore, using metabolomics a greater understanding of the composition of wheat 
grains can be achieved. This may be of use in the future if there is a need to develop 
genetically engineered wheat crops to avoid future shortages and protect from crop 
diseases such as wheat fusarium head blight [55]. A metabolomics approach would 
also provide information relating to crop quality as this is directly related to the 
metabolite content of the plant/grain [55].
- 1 1 5 -
Bran Layer
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Embryo
Figure 4.2: Schematic Diagram of a Wheat Grain Cross-Section: The different 
regions of the wheat grain are annotated on the diagram [561.
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4.7.2 Matrix Selection
A range of matrices have been incorporated into MALDI MS analysis in order to 
assess the potential for metabolomic applications.
Organic matrices have been used in the work described in this chapter namely a- 
CHCA, 5, 10, 15, 20-tetrakis (pentafluorophenyl) porphyrin (F20TPP) and 9- 
aminoacridine. The matrix peaks that are observed with a-CHCA occur in the low 
mass region, interfering with possible metabolites such as amino acids. Therefore 
F20TPP was tested as the matrix peaks associated with this compound are in the high 
mass region, and thus there will be less interference where low mass metabolite 
peaks occurt57].
Inorganic particle suspensions, for example Ti02, Ti02/graphite mix, gold and silver 
nanoparticles, have been investigated as it is thought that they work by a different 
mode of ionisation -  instead of co-crystallising with the analyte it is considered that 
they work by exerting a thermal effect, passing kinetic energy onto the metabolite to 
aid ionisation. Kinumi et a/.[58] have previously reported the use of TiC>2 for small 
molecule analysis. Particle suspension matrices such as TiC>2 [58] and graphite [59] 
have been previously used for small molecule analysis.
4.7.3 Experimental
4.7.3.1 Materials
Trifluoroacetic acid (TFA) (AR grade), a-CHCA, 9-aminoacridine, Titanium 
Dioxide, ethylene glycol, Graphite (1-2 micron, synthetic), F20TPP, acetone and 
ethanol were purchased from Sigma-Aldrich (Gillingham, UK). Potassium gold (III) 
chloride (KAuCL), tetraoctylammonium bromide, dodecanethiol, Gelman Acrodisc 
CR PTFE 0.2pm, silver nitrate (AgNOs) and sodium borohydride were also obtained 
from Sigma-Aldrich (Gillingham, UK). Carbon conductive tape (8x20mm) was 
obtained from TAAB Laboratories Equipment Ltd, Aldermaston, UK. Tape (G304) 
used to affix the plant tissue for initial experiments with the IR laser was obtained 
from Plano GmbH, Wetzlar, Germany.
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4.7.3.2 Instrumentation
UV MALDI
MALDI MS spectra were acquired using an Applied Biosystems/MDS Sciex 
(Ontario, Canada) hybrid quadrupole orthogonal time-of-flight instrument (Q-Star 
Pulsar-i) fitted with a UV MALDI ion source, oMALDI server imaging software and 
a high repetition (1000Hz) Nd:YAG laser with an elliptical spot size of 100x150pm.
UV MALDI (Ion Mobility)
Ion mobility data was aqcuired using a Waters Corporation Synapt™ HDMS™ 
orthogonal time-of-flight instrument fitted with a 200Hz Nd: YAG laser (Manchester, 
UK). Waters MassLynx software was used to process the data.
Matrix Applicator fo r UV MALDI
Airspray deposition of the matrix onto the wheat grain sections was performed using 
an Iwata gravity-fed pneumatic air spray gun (Iwata Media Inc., Portland, OR, USA).
IRLD I
IR LDI mass spectra were acquired using a prototype orthogonal time-of- 
flight mass spectrometer (oTOF MS) equipped with an ErrYAG infrared 
laser (Speser, Spectrum GmbH, Berlin, Germany) that operates at a 
wavelength of 2.94 pm.
The full-width-at-half-maximum (FWHM) duration of the laser pulses was ~ 100 
ps. The mass range for the experiments conducted using IR LDI MS was limited to 
by the setting of the quadrupole - the lower cut off was set to m/z 150.
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4.7.3.3 Sample Preparation Methodology
Wheat (Triticum aestivum L. Var. Axona) plants were grown in Levingtons M3 
compost supplemented with Osmacote in a growth room under a day/night regime of 
20/16°C, a day length of 16 hours and light intensity of 400pE. The developing 
wheat grains were harvested at specified times post-anthesis. Once the wheat grains 
had been harvested, they were instantly frozen using liquid nitrogen to cease any 
further metabolic activity and were then stored at -80°C prior to analysis. A cryostat 
(Leica CM 1900) was used to section the wheat grains. This was done by embedding 
the wheat grain in ice to act as a support. Optimum Cutting Temperature embedding 
medium (OCT) was not used as this is known to suppress MALDI signals [60l  The 
sections were then attached to double-sided carbon conductive tape and freeze dried; 
this was followed by matrix application. For IR LDI the wheat grain sections were 
attached to a different type of double-sided tape [58] and then mounted on a glass slide 
which was then placed into a custom-made milled-out MALDI target plate. This was 
required as preliminary experiments showed that the double-sided carbon conductive 
tape interfered with the analysis, although experiments show that this is not the case 
for UV MALDI MS. Initial experiments were conducted on freeze-dried wheat grain 
sections but it was found that were not as suitable for IR LDI as wheat grain sections 
that had been kept frozen. This is mainly due to the lack of residual water contained 
within the freeze dried sections. Therefore wheat grains that had been sectioned and 
kept frozen were used in these experiments.
4.7.3.4 Matrix Application
An airbrush deposition method was used to apply the matrix as homogeneously as 
possible. The following matrices were studied: a-CHCA, 9-aminoacridine, Titanium 
dioxide/graphite, Silver nanoparticles, Gold nanoparticles and 5, 10, 15, 20-tetrakis 
(pentafluorophenyl) porphyrin.
The matrices were prepared as follows:
a-CHCA: 25mg/mL, dissolved in acetone containing 0.1% trifluroacetic acid (TFA), 
9-aminoacridine: lOmg/mL, dissolved in acetone.
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Titanium dioxide: 5mg/mL suspended in ethanol containing 0.001% ethylene glycol 
and 0.1% TFA.
Titanium dioxide/graphite mix: 5mg/mL, suspended in ethanol containing 0.001% 
ethylene glycol and 0.1 % TFA.
5, 10, 15, 20-tetrakis (pentafluorophenyl) porphyrin was made to a concentration of 
lOmg/mL in ethanol.
The gold nanoparticles were synthesised according to the thiol-derivatisation method 
developed by Brust et al. where the gold salt (KAuCL) was derivatised using 
dodecanethiol and reduced using sodium borohydride (NaBPLO [61]. The silver 
nanoparticles were synthesised using the method developed by Munro et al. where 
silver nitrate solution was reduced using NaBPL [62]. Both the gold and the silver 
nanoparticles were made to a concentration of lmg/mL. All the matrices prepared 
were sonicated for approximately 15 minutes.
4.8 D ata Processing
Calibration was performed using the known matrix masses and selected endogenous 
masses to ensure the mass spectrum was calibrated thoroughly (refer to matrix 
calibration tables in section 4.9). The calculated mass accuracy for the matrix peaks 
formed the basis of the permissible mass accuracy criteria for the allocation of 
masses to potential metabolites. Potential metabolites were detected above these 
ranges that were logical according to metabolism maps; however, these intermediates 
of metabolism were probably too low in concentration to give a defined peak and 
hence the mass accuracy was not as good. In some cases the calibration parameters 
may also have affected the mass accuracy. Thus fewer metabolites were identified 
for both 9-aminoacridine data and F20TPP data as there were fewer matrix 
calibration points that could be used.
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4.9 Results and Discussion
4.9.1 Data Analysis
MALDI MSI generates a large amount of data and the interpretation of this data can 
prove to be challenging.
It has been estimated that there could be around 200 000 metabolites in the plant 
kingdom [31,63]. Many metabolite species are very similar in mass or may even have 
exactly the same mass, and it is difficult to differentiate between isomers. 
Furthermore, adduct formation is a common trait of MALDI MS analyses, and 
therefore sodium and potassium adducts must be considered when interpreting data. 
MS/MS experiments can be beneficially utilised to provide structural information 
regarding a metabolite of interest; however, MS/MS cannot often differentiate 
between isomers [64].
In order to interpret the data generated by MALDI MS the following databases were 
consulted: Metlin [36], MassTrix [37], Kegg [38], MetaCyc [39] and MetaCrop [40]. The 
detected masses were first converted to neutral masses by subtracting the mass of 
hydrogen, sodium and potassium. The neutral masses were also calculated for 
modifications including phosphorylation, hydroxylation and acetylation.
Many metabolites often have similar if not the same masses and trying to assign 
masses to potential metabolites is not an easy task; however, the accuracy of the 
instrumentation used must be taken into account and the degree of error calculated. 
The matrix peaks were used to determine a suitable mass tolerance for the 
metabolites detected. The wealth of data generated by MALDI MS makes it a 
difficult and time consuming process to allocate masses detected to potential 
metabolites; however by including the tables of potential metabolites it is intended to 
highlight the challenges in mass allocation and the complexities of metabolomics 
investigations.
- 121 -
4.9.2 UV MALDI MS
A range of UV matrices were investigated (refer to section 4.7.2) in this study to 
assess how they compare in the ionization of metabolites and whether some matrices 
were better than others for certain types of metabolites such as oligosaccharides, a- 
CHCA was the first matrix to be investigated (see figure 4.3) as it is the most widely 
used matrix in MALDI MSI because it is capable of promoting the ionization of 
many different compounds.
a-CHCA
Figure 4.3 shows a representative MALDI mass spectrum of a wheat grain obtained 
using a-CHCA as the matrix. The matrix peaks shown in table 4.2 are dominant in 
the low mass region (typically under m/z 500) of the MALDI mass spectrum shown 
in figure 4.3. The intensity of these matrix peaks may be suppressing the ionisation 
of metabolites present in the plant tissue, especially low abundance metabolites or 
metabolites may be 'masked' by spectral overlap if the metabolites have the same 
masses as or similar masses to the matrix ions. The sugars are clearly visible in the 
MALDI mass spectrum with the mass assignment of the metabolites detected being 
presented in table 4.3. This table shows the masses that were detected, the 
theoretical mass, the mass accuracy error in both mDa and ppm, the possible 
metabolite detected along with the type of ion detected (protonated, sodiated or 
potassiated) and the possible metabolomic pathways in which the potential 
metabolite may have a role in; this was established using the databases detailed in 
section 4.4. The rationale for the mass assignment to potential metabolites was based 
on the mass accuracy (refer to table 4.2) obtained for the matrix peaks, in this case a 
mass accuracy of approximately 15ppm. In addition, it has to be biologically 
feasible that the metabolites will occur in wheat grain; this was also investigated 
using the metabolomic databases mentioned in section 4.4. Metacrop and MassTrix 
proved to be very useful as they contain information that is directly related to wheat.
However, the presence of the a-CHCA matrix peaks in the low mass region of the 
mass spectrum can be problematic both in terms of potential suppression effects
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where the matrix ions may be suppressing metabolite ions and in terms of potential 
spectral overlap of the matrix ion and the metabolite ions. Matrix suppression of 
metabolites may make the detection of low abundance metabolites virtually 
impossible. The matrix peaks, however, can be beneficial for the recalibration of the 
data post acquisition.
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Figure 4.3: MALDI Mass Spectrum of Wheat Grain: A representative full scan 
spectrum showing the metabolites detected using a-CHCA as the matrix. The 
dominance of the matrix peaks under m/z 500 can interfere with the metabolic 
signals via spectral overlap and suppression effects. This can be problematic as quite 
often in biological tissue there are metabolites that are present in such small 
quantities.
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Mass 
detected m/z
Theoretical
mass
Error
(mDa)
Error
(ppm)
Ion Detected
172.0385 172.0399 -1.40 -8.14 [M+H]+ - H20
190.0508 190.0504 0.40 2.11 [M+H]+
212.0354 212.0324 3.00 14.15 [M+Nap
228.0040 228.0063 -2.30 -10.09 [M+K]+
379.0972 379.0930 4.20 11.08 [2M+H]+
401.0710 401.0750 -4.00 -9.97 [2M+Na]+
417.0498 417.0489 0.90 2.16 [2M+K]+
Table 4.2: Masses obtained for the matrix, a-CHCA.
Mass
detected
m/z
Theoretical
mass
Error
mDa
Error
ppm
Possible metabolite 
detected
Ion
detected
Possible metabolic 
pathways
116.0696 116.0711 -1.50 -12.92 Proline [M+H]+ Arginine and Proline 
metabolism
118.0850 118.0868 -1.80 -15.24 Valine* [M+H]+ Valine, leucine and 
isoleucine degradation
133.0602 133.0613 -1.10 -8.27 Asparagine [M+H]+ Unknown
138.0547 138.0531 1.60 11.59 Proline [M+Na]+ Arginine and Proline 
metabolism
140.0684 140.0688 -0.40 -2.86 Valine* [M+Na]+ Valine, leucine and 
isoleucine degradation
173.0425 173.0426 -0.10 -0.58 Ribose [M+Na]+
175.1170 175.1195 -2.50 -14.28 Arginine * [M+H]+ Arginine and proline 
metabolism
184.0752 184.0738 1.40 7.61 Phosphocholine * [M +Hp Phospholipid Synthesis [65]
219.0250 219.0271 -2.10 -9.59 Hex (Glucose) [M +Kp Sugar metabolism
258.1090 258.1106 -1.60 -6.20 Glycerophosphocholine* [M+H]+ Unknown
363.0725 363.0694 3.10 8.54 Amylose [M +Kp Sugar metabolism
365.1002 365.1060 -5.80 -15.89 Hex 2 (Sucrose)* [M+Na]+ Sugar metabolism
381.0796 381.0799 -0.30 -0.79 Hex 2 (Sucrose) [M+K]+ Sugar metabolism
543.1317 543.1327 -1.00 -1.84 Hex 3 (Raffinose)* [M +Kp Sugar metabolism
582.0535 582.0615 -8.00 -13.74 ADP-ribose* [M +Nap Sugar metabolism
588.0820 588.0744 7.60 12.92 GDP-4-Dehydro-6-
deoxy-D-mannose
[M+H]+ Sugar metabolism
606.0908 606.0850 5.80 9.57 GDP-D-mannose [M +Hp Fructose and Mannose 
Metabolism
628.0662 628.0670 -0.80 -1.27 GDP-D-Mannose* [M+Na]+ Fructose and Mannose 
Metabolism
644.0501 644.0409 9.20 14.29 GDP-D-Mannose [M+K]+ Fructose and M annose 
Metabolism
705.1857 705.1856 0.10 0.14 Hex 4 (Stachyose) * [M +Kp Sugar metabolism
867.2356 867.2384 -2.80 -3.23 Hex 5* [M+K]+ Sugar metabolism
Table 4.3: Potential metabolites detected using a-CHCA as the matrix:
Metabolites marked with an asterisk (*) correspond to the images presented in figure 
4 .4 .
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Table 4.2 shows the calculated matrix errors of the matrix ions detected. The 
tabulated data (Table 4.3) of potential metabolites shows the errors in both mDa and 
in ppm. This was done for data comparison between the data generated herein and 
the data contained in published literature where the errors are reported in mDa and 
larger mass accuracy errors are often reported [66]. The metabolites shown in table
4.3 are mostly primary metabolites; these are compounds that are essential to life [20].
4.9.3 Interpretation of MALDI MS Images
Each pixel in the MALDI image relates to the mass spectrum recorded at that point. 
The brightness of the pixel can be indicative of the relative concentration of the 
metabolite in that location, although it is important to note that this is not an accurate 
method of quantification and gives only semi-quantitative information.
Figure 4.4 shows the MALDI images generated using a-CHCA that correspond to 
some of the metabolites in table 4.3; these are marked with an asterisk (*). Images a 
and b show the tentative distributions of valine ([M+H]+ and [M+Na]+, respectively) 
where the images show that valine in its protonated form is more abundant 
throughout the wheat grain section. Image c is the distribution for m/z 175.12 
tentatively assigned to arginine ([M+H]+) and this ion appears to be more abundant at 
the top of the wheat grain section. The image labelled d shows that there is a 
relatively homogenous distribution throughout the endosperm regions of the wheat 
grain section of m/z 184.07; this has been tentatively assigned to the presence of 
phosphocholine. Image e is the image obtained for m/z 258.11 and shows the ion 
intensity is greater at the top and centre of the wheat grain section; this mass was 
tentatively assigned to glycerophosphocholine. Image f  is that obtained for m/z 
365.10, which has been tentatively assigned to the sodium adduct of sucrose. Image 
g shows the distribution of 543.13 which has been tentatively assigned to a hexose 3 
sugar such as Raffinose; the distribution is similar to that observed for image f. 
Image h shows the distribution of m/z 582.05 which has been tentatively assigned to 
ADP-ribose. Images i, j and k, tentatively assigned to the presence of sodiated GDP- 
D-Mannose, Hex 4 sugar (potassiated), for example Stachyose, and Hex 5 sugar 
(potassiated), respectively, all appear to be less abundant than in the previous images 
- this is probably due to the abundance of the ion within the wheat grain section.
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Figure 4.4: MALDI MS Images of Wheat Grain: The accurate MALDI MS 
images of m/z: (a) 118.09; (b) 140.07; (c) 175.12; (d) 184.07; (e) 258.11; (0  365.10; 
(g) 543.13; (h) 582.05; (i) 628.07; (j) 705.19 and (k) 867.24. Images were 
normalised to the corresponding matrix ion.
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F20TPP
Due to the expense of F20TPP this matrix was tested for its use in plant metabolomic 
analysis by manually spotting the matrix onto the surface of the wheat grain tissue 
section. Therefore an image for this particular matrix was not generated.
[M]
I
Q957184 0736 263 Q354v^3Q4_2998
m/z
Figure 4.5: MALDI Mass Spectrum of Wheat Grain using F20TPP. A
representative full scan MALDI mass spectrum showing the metabolites obtained 
using F20TPP. As can be seen in the spectrum, the matrix peaks occur at the higher 
mass end of the spectrum with the main peak for [M |+ occurring at m/z 974.0545.
The masses presented in table 4.4 are related to the mass accuracy of the matrix 
peaks. As the matrix peaks for F20TPP occur in the high mass region, the peaks 
used for the calibration included a fragment ion observed at m/z 807.07 and an 
endogenous peak at m/z 184.07 was used as this peak was common to all the UV 
MALDI MS experiments conducted in positive ion mode.
The metabolites potentially identified using this particular matrix have errors that are 
quite large as shown in table 4.5; this was probably due to the lack of calibration
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points over a suitable mass range. The metabolites that were tentatively identified 
appear to be secondary metabolites; these are metabolites that operate in biochemical 
reactions and in signalling cascades [20]. This is plausible as there are no matrix ions 
in the low mass region to suppress less abundant secondary metabolites. The 
databases used as previously described gave an insight into some of the potential 
pathways associated with these tentatively identified metabolites. The strong 
intensity for the matrix ion at m/z 974.05 seems to have suppressed the ionisation of 
the sugars identified previously using a-CHCA as the matrix.
Mass detected 
m/z
Theoretical
Mass
Error mDa Error ppm Ion Detected
184.0735 184.0734 0.10 0.54 [Phosphocholine+H]+
807.0711 807.0711 0.00 0.00 [Fragment ion -1R
group
974.0545 974.0586 -4.10 -4.21 [M]+
Table 4.4: Masses Obtained for the Matrix F20TPP.
Mass
Detected
m/z
Theoretical
mass
Error
mDa
Error
ppm
Possible Metabolite Ion
detected
Possible
metabolic
pathway
184.0735 184.0739 -0.40 -2.17 Phosphocholine [M+H]+ Phospholipid 1 
synthesis [66]
270.0342 270.0379 -3.70 -13.70 N-acetyl-5-glutamyl phosphate [M+H]+ Arginine
biosynthesis
277.0294 277.0325 -3.10 -11.19 6 phosphogluconate [M +H p
289.0379 289.0324 5.50 19.03 3-deoxy-arabino-heptulosonate 7- 
phosphate
[M+H]+ Shikimate
biosynthesis
291.0501 291.0481 2.00 6.87 Sedoheptulose 7-phosphate [M +H p Pentose
phosphate
pathway/Calvin
cycle
309.0435 309.0464 -2.90 -9.38 N 1 -(5-phospho-D-ribosyl)glycinamide [M+Na]+ Purine
biosynthesis
450.0129 450.0191 -6.20 -13.78 ADP [M+Na]+ Multiple
pathways
455.0805 455.0815 -1.00 -2.20 (S)-2-[5-am ino-1 -(5-phospho-D- 
ribosyl)imidazole-4- 
carboxam ido] succinate
[M+H]+ Purine
biosynthesis
502.0421 502.0376 4.50 8.96 N6-( 1,2-dicarboxyethyl)-AMP [M +K p Purine
biosynthesis
505.1736 505.1766 -3.00 -5.94 1 -kestose [M +H p Fructan
biosynthesis
537.0517 537.0523 -0.60 -1.12 UDP-L-arabinose [M +Hp Arabinoxylan,
Beta-Glucan,
cellulose
biosynthesis
582.0556 582.0613 -5.70 -9.79 Phosphoribosyl-AMP [M +Nap Histidine
biosynthesis
Table 4.5: Potential Metabolites Detected using F20TPP as the Matrix
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9-aminoacridine
The following MALDI mass spectrum was acquired in negative ion mode using 9- 
aminoacridine as the matrix.
The most prominent peak in the mass spectrum occurs at m/z 193.07 which is the 
[M-HL of 9-aminoacridine.
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Figure 4.6: MALDI Mass Spectrum of Wheat Grain using 9-aminoacridine:
The spectrum shows the metabolites obtained using 9-aminoacridine as a matrix in 
negative ion mode MALDI. The most prominent matrix peaks can be clearly seen in 
the spectrum at m/z 193.07. As with other organic matrices these intense matrix 
signals may have a suppression effect on the metabolites.
The results of the imaging experiments obtained using 9-aminoacridine as the matrix 
in negative ion mode are shown in figure 4.7. The image on the left is the optical 
image of the wheat grain section that has been coated with matrix. The MALDI MS 
images show the tentative distribution of [M -Hf of sucrose at m/z 341 and [M-HL 
of glucose 6 -phosphate at m/z 259, respectively.
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Both of the images shown have been normalised to the corresponding matrix mass at 
m/z 193.07 to account for any potential discrepancies with the matrix coverage of the 
section.
Figure 4.7: MALDI-MS Images of Wheat Grain using 9-aminoacridine:
MALDI-MS images of a wheat grain section at 16 dpa obtained in negative ion mode 
using 9-aminoacridine as the matrix. Images were normalised to the corresponding 
matrix mass at m/z 193.07. The image on the left is the optical image of the wheat 
grain section that has been coated with matrix, followed by the MALDI MS images 
for [M-H]" of sucrose at m/z 341 and [M-H]" of glucose 6 -phosphate at m/z 259, 
respectively. The colour intensity of the image represents the abundance of the ion 
being imaged with red representing the locations at which the ion is most abundant 
and black representing zero abundance.
Observed m/z Theoretical m/z Error mDa Error ppm Ion detected
193.0725 193.0766 -4.10 -21.24 [M-H]
385.1402 385.1453 -5.10 -13.24 [C26H I7N4]’
Table 4.6: Masses Obtained for the Matrix 9-aminoacridine.
Observed Theoretical Error Error Possible Metabolite Ion Possible metabolic
m/z m/z mDa ppm Detected Detected pathways
145.0607 145.0613 -0.60 -4.14 Glutamine [M-H]' Glutam ine/Glutamate
metabolism
179.0631 179.0556 7.50 41.89 Hexose Sugars [M-H]' Sugar metabolism
259.0322 259.0219 10.30 39.77 Glucose 6-phosphate [M-H] Sugar metabolism
341.1297 341.1084 21.30 62.44 Sucrose [M-H] Sugar metabolism
Table 4.7: Potential Metabolites Detected using 9-aminoacridine as the Matrix.
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Inorganic Matrices
Other matrices that have been investigated included particle suspension matrices and 
nanoparticles. These proved to be of limited use; this is probably due to these types 
of matrix not co-crystallising with the metabolites contained within the wheat grain 
section.
1000
Figure 4.8: MALDI Mass Spectrum of Wheat Grain using TiC^: The spectrum 
demonstrates that Ti0 2  is a poor matrix for this particular application due to the poor 
signal intensity.
Gold and silver nanoparticles were also investigated. It was found that these 
matrices were not as good as conventional MALDI matrices in promoting efficient 
ionisation of many different types of compounds.
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Figure 4.9: MALDI Mass Spectrum of Wheat Grain using Gold Nanoparticles:
As with TiCL the signal intensity is poor, therefore few metabolites were detected 
using this matrix.
Figure 4.10: MALDI Mass Spectrum of Wheat Grain using Silver Nanoparticles.
4.9.4 Metabolite Profiling in Wheat Grains by MALDI-Ion 
Mobility Separation Mass Spectrometry
Ion mobility separation combined with MALDI MS was investigated in an attempt to 
reduce the matrix interference in the low mass region as previously observed in 
section 4.9.2.
Ions are separated according to their size:charge ratio in a drift tube containing buffer 
gas under the influence of an electric field. Ions are accelerated through the electric 
field and undergo collisions with the buffer gas [67]. Once separated on the basis of 
size the ions enter the time-of-flight where the m/z is measured.
Experiments were conducted using a Waters Corporation Synapt™ HDMS™ 
instrument [68] fitted with a 200Hz Nd: YAG laser; this is the next generation 
orthogonal time-of-flight instruments developed and manufactured by Waters 
replacing their QTOF Premier instrument.
Wheat grain sections were prepared as previously described in section 4.7.3.3.
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Figure 4.11: A Schematic of the Waters Corporation Synapt™ HDMS™ System.
Image supplied by Dr M. Snel, Waters, UK.
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As many metabolites have masses that are exactly the same as those of other 
metabolites, ion mobility has been performed to try to separate metabolites according 
to their shape/structure. As wheat is known to contain sugars such as sucrose, ion 
mobility was used to investigate if sugars of the same molecular mass could be 
differentiated. The experiments conducted, using conventional MALDI with 
standards, showed that isomeric sugars could not be separated.
In another set of experiments to separate the isomeric sugars, sucrose and lactose 
were analysed by conventional MALDI MS analysis using a-CHCA as the matrix. 
Two structurally different compounds had been identified (refer to figure 4.12); 
however, these were later found to be sucrose and the second isotopic peak of the 
protonated matrix dimer occuring at m/z 381.09 (that was present in the trendline 
associated with the matrix).
Sucrose m/z 
381.08
Matrix isotope 
m/z 381.09
t 380
Dftft Time (B in#)
(0 04 ,0  20) C1_r<W)<10_501)
Figure 4.12: Driftscope Data Analysis of m/z 381: Isotopic separation of the 
potassiated sucrose ion at m/z 381.08 and the second isotope peak of the protonated 
matrix dimer at occuring at m/z 381.09.
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The driftscope data is presented in figure 4.13, and it shows that there are three 
trendlines within the dataset obtained from wheat grain sections that had been 
prepared as previously described in section 4.7.3.3 using a-CHCA as the matrix.
The spectra in figure 4.14 show that the sugars dominate the spectra and although 
three different trendlines can be observed in figure 4.13, the instrument is unable to 
fully separate out the sugars. This is probably due to the mass resolution of the 
instrument[69].
Figure 4.13: Driftscope Data Analysis of a Wheat Grain Section: There are three 
visible trendlines in the data; these are referred to as 1,2 and 3.
Trendline 1 shows the sugar distribution.
Trendline 2 shows the matrix peaks.
Trendline 3 shows possible lipids.
- 1 3 6 -
1173.3473s ,1518.4738 
1659.5175 
1553.4348 1 k fellI H " ii"Tnrn
1600 1700
- 137-
1519 4811 ) ,82,5B8^
Figure 4.14: MALDI Mass Spectra of Driftscope Trendlines of Wheat Grain.
Spectrum A) represents the full dataset acquired on a wheat grain section, B) shows 
the trendline marked 1 (in figure 4.13) which is assigned to the presence of sugars, C) 
represents the data from trendline marked 2 (in figure 4.13), D) relates to the 
trendline marked 3 that could possibly be due to the presence of lipids.
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Although isomeric separation was not achieved using ion mobility, class separation 
of structurally related compounds was achieved as can be seen by the three trendlines 
that can be clearly observed in figure 4.13 and this is useful in itself.
4.9.5 IR LDI MS
Analysis was also performed using IR LDI MS with an Er: YAG laser. This 
approach does not require a chemical matrix as the residual water in the sample acts 
as the matrix. The real elegance with this particular approach is that there are no 
interfering matrix peaks or matrix suppression effects and therefore all the peaks 
observed are sample related. There is also no risk of analyte translocation/diffusion 
that is sometimes observed during matrix application for UV MALDI MS. The IR 
laser ablates more of the sample and it was observed that it ablated through to the 
conductive tape on which the sample was mounted, causing contaminant peaks 
arising from the ionisation of the tape. Therefore, it was decided to use fresh, frozen 
tissue mounted onto glass slides and metabolite profiling experiments were carried 
out; each profile was acquired over 2 minute period. The data was recalibrated using 
the following sugar masses: Hex [M+K]+ at m/z 219.027, Hex 2 [M+K]+ at m/z 
381.080, Hex 3 [M+K]+ at m/z 543.133, Hex 4 [M+K]+ at m/z 705.186 and Hex 5 
[M+K]+ at m/z 867.238. The results show that ions from the oligosaccharides 
dominate the spectra, the most apparent being the potassiated adducts. The mass 
range for the metabolite profiling experiments was limited by the quadrupole setting 
with the lower cut off set to m/z 150. The spectra (figures 4.15 and 4.16) show that 
there are clear differences between the embryo and endosperm regions of the wheat 
grain. The endosperm appears to contain more of the higher mass storage sugars, 
whereas the embryo seems to contain more of the smaller sugars, such as sucrose, 
which are needed for growth. Fresh frozen tissue worked better for this analysis as 
although the same patterns of metabolites were observed; tissue that had been freeze 
dried gave poor intensity spectra. Using the IR laser a very interesting effect was 
observed in that the signal intensity dramatically increased after the laser had fired 
for approximately 1 minute.
- 139-
o CM
4 5 0 -
<o
P0O'
1 0 coU")
O)K.O)
o>
CoCM <D*oO)
T" 'Ok o>toO )
CM
CO
o>CMCOCOCOOCT> >—,C\I jtkteU
rooo200
7000-
10<j>
CM
CO s >  0  " O  O) o>
00o
00co
ll I l . . ” i j 7 . . L  . p - l
Co
2°
200 m/z 1000
Figure 4.15: IR  LDI Mass Spectra of Wheat Grain Embryos: Embryo spectra 
taken under the same mass spectrometry conditions from 2  different wheat grains at 
the same developmental stage ( 1 2  days post-anthesis).
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Figure 4.16: IR LDI Mass Spectra of Wheat Grain Endosperms: Endosperm 
Spectra -  Taken under the same mass spectrometry conditions from 2 different wheat 
grains at the same developmental stage (12 days post anthesis).
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Observed
m/z
Theoretical
m/z
Error
mDa
Error
(ppm)
Potential Metabolite Ion
detected
Possible Metabolite 
Pathway
185.0320 185.0329 -0.90 -4.86 Glutam ine [M +K p Arginine biosynthesis
219.0260 219.0271 -1.10 -5.02 Hexose [M +K p Sugar metabolism
261.0330 261.0311 1.90 7.28 Cystathionine [M +K p Methionine
biosynthesis
291.0470 291.0481 -1.10 -3.78 Sedoheptulose 7- 
phosphate
[M +Kp Pentose phosphate 
pathway
298.9940 298.9935 0.50 1.67 Mannose 6-phosphate [M +Kp Ascorbate
biosynthesis
363.0710 363.0693 1.70 4.68 Hex 2 (-H20) [M +K p Sugar metabolism
381.0810 381.0799 1.10 2.89 Hex 2 [M +Kp Sugar metabolism
423.0900 423.0903 -0.30 -0.71 Sucrose 6-phosphate [M +Kp Sucrose breakdown
525.1240 525.1211 2.90 5.52 Hex 3 (-H20 ) [M +Kp Sugar metabolism
543.1300 543.1317 -1.70 -3.13 Hex 3 [M +K p Sugar metabolism
567.1370 567.1317 5.30 9.35 Ac-Hex 3 (-H20 ) [M +Kp Sugar metabolism
585.1470 585.1423 4.70 8.03 Ac-Hex 3 [M +K p Sugar metabolism
671.1800 671.2011 -21.10 -31.44 Hex4 (-H20 ) [M +Nap Sugar metabolism
687.1760 687.1750 1.00 1.46 Hex 4 (-H20 ) [M +K p Sugar metabolism
705.1840 705.1856 -1.60 -2.27 Hex 4 [M +K p Sugar metabolism
747.2020 747.1962 5.80 7.76 Ac-Hex 4 [M +K p Sugar metabolism
831.2270 831.2183 8.70 10.47 Hex 5 -(2H20 ) [M +Kp Sugar metabolism
849.2370 849.2289 8.10 9.54 Hex 5 ( H20 ) [M +Kp Sugar metabolism
867.2400 867.2395 0.50 0.58 Hex 5 [M +K p Sugar metabolism
909.2620 909.2501 11.90 13.09 Ac-Hex 5 (-H:0 ) [M +K p Sugar metabolism
Table 4.8: Potential Metabolites Detected using IR LDI MS.
It is clear from the IR LDI data that a small number of metabolites are observed in 
apparently high concentrations, for example hexose sugars. The results confirm what 
one would assume; viz. that the endosperm region contains higher mass hexose 
sugars than the embryo region, which contains mainly sucrose. As the endosperm is 
the major sugar storage area of the wheat grain it would be expected to contain 
higher mass sugars. This distribution in sucrose also corresponds with the data 
obtained in negative ion mode where the sucrose distribution was predominantly in 
the embryo region of the wheat grain section. The oligosaccharide peaks are more 
apparent in the IR LDI data. This is probably because the oligosaccharides are 
ionised better with the infrared laser, there are no interfering matrix peaks that could 
suppress the sugar peaks as in UV MALDI MS, and the tissue was not freeze dried.
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However, the intense oligosaccharide peaks may be suppressing other metabolites 
contained within the wheat grain section. A common observed modification that is 
apparent from the IR data is the acetylation of the sugars. The presence of sugars in 
a range of plant materials has also been previously reported in fruits [70] and in wheat 
stems t71’72].
4.10 Conclusion
Mass spectrometry is now widely used in metabolomics studies and it has been 
demonstrated in this chapter that the use of UV MALDI MS alone or with imaging 
capabilities (MALDI MSI) can be utilized in such an area. As with any technique 
there are always disadvantages in this case interfering matrix peaks. When analysing 
plant tissue this can be very important as often some metabolites are in extremely 
small concentrations and any suppression effects could hinder their detection. This is 
apparent in mass spectrometry-based metabolomics studies when the 
chromatographic step seen with LC-MS and GC-MS is omitted; these techniques are 
still probably better for the detection of less abundant secondary metabolites. 
However, there are also many advantages with MALDI MSI; one of the most 
important is the ability to spatially locate where metabolites occur in plant sections 
and the ability to detect many different masses in parallel whether they are known or 
unknown.
Metabolomic investigations using IR LDI MS proved to be very useful and 
informative as all the information generated was sample related and lacked the 
matrix peaks and suppression effects often seen with UV MALDI MS. Using IR 
LDI MS the oligosaccharide peaks and the ratios between the peaks are much more 
visible.
There are so many variables that have been discussed within this chapter that can 
affect the metabolic profile/status of plant material, and a compromise between 
preserving the metabolic status while preparing the sample in a suitable way for the 
analysis to be performed must be consistently achieved. Freeze drying of the tissue 
was done to preserve the metabolic status of the tissue. However, this could have 
affected the results obtained by potentially reducing the metabolite extraction and co­
crystallisation efficiency between the matrix and metabolite molecules. To 
overcome this limitation the tissue could have been rehydrated or to incorporate 
more sample wetting in the matrix application procedure; however, this could result 
in the delocalisation of metabolites and therefore not produce a true biological 
representation. As a typical image run with a resolution of 100pm x 100pm took 
approximately 6 hours for image acquisition there was a need to incorporate the 
freeze drying step as otherwise metabolic processes could still feasibly occur in the 
sample while in the mass spectrometer. However, for the experiments conducted 
with the IR laser the freeze drying process somewhat hindered the analysis; this is 
not surprising as it is thought that residual water contained within the samples acts as 
a matrix. The more intense sugar peaks could be attributed to the use of fresh tissue 
as opposed to the freeze dried tissue used for UV MALDI MS experiments; the sugar 
peaks dominate the spectra which could suppress other less abundant metabolites 
within the tissue.
Data analysis can be both a complex and time-consuming process, especially for the 
UV MALDI data as this includes the matrix peaks.
Metabolite databases are more established for GC and LC-MS analyses. However, 
there are databases where masses along with their corresponding intensities can be 
searched. The major problem with this type of non-targeted approach is that the 
metabolite database may match metabolites up with the observed masses but these 
compounds may not be native to the type of tissue under investigation. For example, 
drug metabolites may be of the same mass as a plant metabolite. Therefore, an in- 
depth knowledge of the plant tissue investigated needs to be established before trying 
to match up the observed masses with potential metabolites. Metacrop, a database 
that contains information on crop plants, proved very useful for this purpose as it 
contains information regarding the metabolites in specific examples of plant tissue 
[41]. Another issue is that there are so many metabolites that are biologically feasible 
that can be supported by metabolic pathways; however, the masses that are detected 
often differ to an unacceptable level for mass spectrometric measurement. This is 
highlighted in the publication of Li et al. where some of the reported mass errors are 
up to 44mDa [66]. This factor could potentially be reduced by decreasing the mass 
range in an attempt to increase the sensitivity; however, this defeats the point of the
non-targeted approach and it becomes more of a selective process depending on the 
metabolites that are of interest.
The calibration of the instrument prior to sample analysis and the subsequent 
recalibration of data are very important in ensuring that data obtained is as accurate 
as possible. Hundreds of mass signals are obtained from a MALDI imaging 
experiment but assignment of masses is still limited by the lack of complete 
databases and standards, particularly of secondary metabolites.
The mass list obtained using a-CHCA and IR LDI MS shows the sugar distributions; 
however, the mass list obtained using 9-aminoacridine and F20TPP shows fewer 
metabolites. This could be due to the data recalibration procedure - the use of 2-3 
calibration points seems to be insufficient for the mass accuracy required for 
metabolomic studies. This method of recalibration could be improved upon by using 
a spiked solution containing commercially available standards combined with matrix 
for both the instrument calibration prior to analysis and for the recalibration. This 
approach could also provide information relating to ion suppression effects as 
detailed by Vaidyanathan et al.[73].
The development of appropriate software for high throughput metabolomics using 
MALDI is crucial to future analyses. Software is currently available from Waters 
(MSe) for LC-MS analyses that enable the user to acquire MS and MS/MS data 
simultaneously [74]. A similar approach would be useful for MALDI analyses as this 
would immediately eliminate the matrix peaks observed from the endogenous 
compounds contained within the sample of interest and help in the identification of 
unknown masses. There is a lack of complete databases for metabolomic studies. 
The development of metabolite searching software would be beneficial as many 
databases can contain metabolites that are found in many organisms and they don't 
always take into account the adducts that are commonly formed in MALDI analyses. 
Therefore, in some instances the data has to be converted into the corresponding 
neutral masses.
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Chapter 5
Method Development for the Application of 
MALDI MSI to Animal Models of Disease: 
A Preliminary Study of Spinal Cords from 
Mice with Chronic Relapsing Experimental 
Autoimmune Encephalomyelitis
5.1 Introduction to Mammalian Metabolomics
The term metabolomics has previously been defined in chapter 4 in the context of 
plant tissue; in this chapter metabolomics has been applied to the study of animal 
tissue.
This chapter details a mammalian metabolomics approach for the study of spinal 
cords from mice with CREAE (Chronic Relapsing Experimental Autoimmune 
Encephalomyelitis), the animal model of multiple sclerosis. A non-targeted strategy 
was used in an attempt to discover differences between healthy and diseased tissues 
i.e., to identify potential biomarkers of disease. A main focus of the work presented 
in this chapter was to establish methodology with respect to the sample preparation 
procedure required for the mass spectrometric analysis of CREAE spinal cord 
samples.
Metabolomics is a relatively new addition to the 'omics sciences and it is gaining 
much interest. A major application of metabolomics is in the quest for metabolic 
markers of disease. In diseases such as multiple sclerosis, biomarker discovery plays 
a pivotal role in the development of new treatments and could eventually prevent 
symptoms from worsening by early disease management[1].
Metabolomics-based approaches have previously been used to study animal models 
of human diseases such as cancer [2], cardiovascular disease t3] and Alzheimer's 
disease [4].
5.2 Biomarkers
Biomarkers are compounds that are indicative of the physiological or pathological 
status of cells/tissues. The discovery and identification of biomarkers are important 
for early disease detection. Advances in molecular biology and improvements in 
instrumentation have allowed for more high-throughput analyses in the area of 
biomarker discovery [5]. The 'omics, in particular proteomics and more recently 
metabolomics, have become very popular in disease profiling experiments with the
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ultimate aim of identifying potential biomarkers that are indicative of disease 
pathogenesis.
5.2.1 The Role of Mass Spectrometry in Biomarker Discovery
Mass spectrometry has a pivotal role in biomarker discovery due to its unparalled 
sensitivity. It allows for rapid analysis to gain qualitative and quantitative 
information and is operational over a large dynamic range [61. Biomarkers of disease 
may be unknown, they may occur in minute quantities and they may be up or down 
regulated in diseased samples [7].
Until recently, the majority of biomarker related experiments have been conducted at 
the proteome level. Hyphenated mass spectrometry techniques such as LC-MS and 
LC-MS/MS have been extensively utilised for the detection and identification of 
protein biomarkers of disease; examples include the analysis of synovial fluid and 
serum from rheumatoid arthritis patients [8] and biomarkers indicative of breast 
cancer progression in cell lines [9]. MALDI-TOF-MS has been used to analyse 
cerobrospinal fluid from multiple sclerosis patients and to identify three proteins that 
were associated with the disease |l()|. MALDI MSI has also been used to profile 
myelinated and demyelinated regions in mouse brain [ll].
There is now increasing interest in the role of metabolomics in biomarker discovery 
as the biochemical pathways of metabolism can be altered in some diseases [12]. 
Non-targeted metabolomic experiments using LC-MS and GC-MS have been used to 
investigate biomarkers of drug induced nephrotoxicity with data indicating that 
increased levels of polyamines and amino acids were potential biomarkers [13].
SIMS and MALDI MSI have been previously used for the detection and imaging of 
metabolites and peptides in the spinal cords of rats [14].
5.3 Introduction to Multiple Sclerosis
Multiple sclerosis is often regarded as a disease of the western world as it is more 
prevalent in the northern European and North American populations; this has led
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researchers to hypothesise a potential link between environmental factors and the 
development of multiple sclerosis. Britain is categorised as having a high incidence 
of multiple sclerosis with -85 000 people suffering from the condition [15].
Multiple Sclerosis is an autoimmune condition of unknown etiology, where the white 
blood cells (particularly T cells) mount an attack on the central nervous system 
(CNS). This results in damage to the myelin sheaths that protect the nerves, resulting 
in demyelination and the loss of oligodendrocytes, and thus disrupting nerve 
signals/conduction [16, 17]. A common pathological feature associated with multiple 
sclerosis is the lesions that present themselves most frequently in the white matter, 
although they have been less commonly observed in gray matter. The lesions can be 
observed both in the brain and in the spinal cord Ll8]. It has been reported that spinal 
cord lesions can be present without any lesions appearing in the brain [19]. There is 
also evidence to support a correlation between spinal cord lesions and the level of 
disability in patients with multiple sclerosis [20].
5.3.1 Techniques Used for the Study of Multiple Sclerosis
The diagnosis of multiple sclerosis is not straightforward. It is based on clinical 
symptoms, magnetic resonance imaging (MRI) results [2,] and electrophoresis of 
cerobrospinal fluid obtained by lumbar puncture to detect oligoclonal 
immunoglobulin bands [22]. This lumbar puncture is, however, an invasive 
procedure. In recent years there has been much research into the discovery of 
biomarkers of disease; these experiments are usually proteomic or metabolomic 
investigations. Many techniques have been adopted to study multiple sclerosis; 
however; the majority of studies have focussed on the more obvious disease aspects 
such as loss of myelin and lesion formation. Proton magnetic resonance 
spectroscopy has been used to obtain pathological information non-invasively from 
multiple sclerosis patients [23]. The benefits of this technique are that human samples 
can be studied, therefore avoiding the animal model versus human debate. A number 
of small molecule biomarkers have been previously investigated in multiple 
sclerosis; the most common include choline, creatine and N-acetyl aspartate [24' 25]. 
The published literature describes both an increase in choline 124 261 and a decrease of
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choline levels in multiple sclerosis [26]. The metabolite studies conducted by Inglese 
et al. showed from their cell culture experiments that the concentrations of choline 
and creatine were elevated in astrocytes and oligodendrocytes in multiple sclerosis 
patients
5.3.2 Animal Models of Multiple Sclerosis
5.3.2.1 Chronic Relapsing Experimental Autoimmune 
Encephalomyelitis (CREAE)
CREAE is a T-cell mediated inflammatory, demyelinating condition of the central 
nervous system. CREAE is used as an animal model of multiple sclerosis to allow 
the pathogenesis of the disease to be studied. CREAE can be initiated by active 
immunisation using spinal cord homogenate or purified myelin components that are 
combined with adjuvants such as Freund's and Mycobacterium Tuberculosis. The 
inoculated animals go on to develop either acute monophasic or chronic relapsing 
disease depending on the inoculation schedule used [27]. The use of animal models 
that mimic human diseases is of paramount importance in gaining a greater 
understanding of the associated disease pathogenesis. Animal models provide a way 
of studying diseases which could not be directly studied in humans, for example the 
study of the central nervous system (CNS) in multiple sclerosis. At present three 
drugs for the treatment of multiple sclerosis (Glatiramer acetate, Mitoxantrone and 
Natalizumab) have been developed from EAE models [28].
The main advantages of using the CREAE model are as follows:
■ Enables researchers to study the cellular processes underpinning multiple 
sclerosis in particular demyelination that may help to determine the cause of 
multiple sclerosis.
■ Tests potential therapeutic strategies for use in the treatment of multiple 
sclerosis.
■ As CREAE experiments most commonly use rodents, experiments are 
relatively short due to their fast breeding.
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The disadvantages of using this animal model are:
■ CREAE is an ‘animal model’ of multiple sclerosis and this is mainly based 
upon preconceived ideas on multiple sclerosis pathogenesis.
■ Animal testing.
A compromise must be achieved between the number of animals used for a particular 
study and the statistical reproducibility. This includes the number of biological 
replicates as biological variability can affect the results that are obtained; however, it 
is apparent in many publications that repeat examinations have been performed on 
tissue from the same animal for evaluation of the measurement process. This 
provides no information on biological variability at all [29].
5.4 Experimental Part I: CREAE Induction
CREAE induction was undertaken at Queen Mary’s University, London and was 
performed as previously described by Baker et al. [30] under the home office licence 
of Dr C. Bolton.
5.4.1 A Brief Overview of CREAE Induction
Complete Freund’s adjuvant (CFA) was produced by mixing 16pg Mycobacterium 
tuberculosis H37Ra and 4pg Mycobacterium butyricum in 4mL of incomplete 
Freund’s adjuvant (IFA) (all Difco Laboratoris, Detroit, Michigan, USA) and kept at 
4°C. lmL of the CFA stock was added to 11.5mL of IFA to make up 12.5mL CFA 
for the inoculation emulsion. Spinal cord tissue obtained from Biozzi antibody high 
(ABH) mice was homogenised and freeze dried; 33mg of the freeze dried tissue was 
reconstituted in 5mL phosphate buffered saline (PBS). The reconstituted spinal cord 
was added to an equal volume of CFA and then sonicated for 10 minutes at room 
temperature. This mixture was then drawn up and down in a lm L syringe to 
emulsify the solution until it could not be dispersed further.
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5.4.2 Inoculation of Biozzi ABH Mice
0.15mL of the emulsion, described previously in section 5.4.1, was injected 
subcutaneously into each flank of the Biozzi ABH mice at time points day 0 and day 
7. Post acute phase, some of the mice spontaneously relapsed. If the mice did not 
relapse a further injection of 0.15mL of the emulsion was used to induce the relapse
[30]. Each injection that was administered was equivalent to lmg of lyophilised 
Biozzi ABH mouse spinal cord homogenate and 60pg of mycobacteria. Mice were 
then assessed using a CREAE score on a daily basis using the criteria shown in 
figure 5.1.
Weight loss was the first observed clinical sign at approximately 13-15 days post 
inoculation. This was followed by neurological deficit (limp tail) at approximately 
15-17 days post inoculation. Acute paralysis was observed at approximately 18-20 
days post inoculation, where the paralysis was sustained for approximately 4 days 
(days 20-24 post inoculation); mice gained weight in this period. The first remission 
was observed between days 24 and 28 where some tail tone was regained (not fully 
regained). The mice went into a spontaneous relapse between days 35 and 40 post 
inoculation, with the onset of rapid paralysis. In mice that did not suffer spontaneous 
relapse, the relapse was induced by administering a third injection of the spinal cord 
emulsion as previously described. Approximately 6 - 8  days post inoculation induced 
relapse was achieved and the mice developed severe paralysis from which they 
developed chronic disease.
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Figure 5.1: Stages and Levels of Disability Associated with CREAE: A graph to 
show the stages and levels of disability associated with the disease stages studied in 
this chapter. Adapted from [31].
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5.4.3 Tissue Removal Procedure
Biozzi ABH mice were sacrificed under the schedule one method of the Home 
Office, UK regulations. Mice were sacrificed at the following stages: predisease, 
acute stage disease, relapse, first remission and second remission. Spinal cords were 
removed by flushing out using using approximately l-2mL of ice cold PBS, 
containing Indomethacin, a cyclooxygenase inhibitor, at a concentration of lOjig/ml 
contained in the PBS solution (to inhibit further Prostaglandin production that occurs 
during the disruption of dissection). The PBS solution was made to the following 
concentrations by dissolving one PBS tablet in 200mL of Ultra High Quality (UHQ) 
water: 137mM NaCl, 2.7mM KC1 and lOmM phosphate buffer solution (pH 7.4 at 
25°C). Not only does the PBS aid in the removal of the spinal cords, it removes any 
blood from the tissue surface, which if left could interfere with the prostaglandin 
levels. The spinals cords were then snap frozen using isopentane and liquid nitrogen. 
Tissue was stored at -80°C until required.
5.5 Experimental Part II: Materials and Methods for MALDI MSI 
Analysis
5.5.1 Materials
Ethanol (HPLC grade), trifluoroacetic acid (TFA, HPLC grade), a-CHCA, 
carboxymethylcellulose (CMC), Harris's haematoxylin, eosin, DPX mounting 
medium, xylene, glass microscope slides and choline base standard solution were 
obtained from Sigma Aldrich, Gillingham, UK.
Cryomoulds were obtained from Fisher Scientific, Loughborough, UK.
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5.5.2 Sample Preparation for MALDI MSI Analysis
D isease Stage
Control Animal 
Num ber (un­
inoculated)
Un-inoculated 
Animal W eight (g)
Diseased Animal 
Number 
(inoculated)
Inoculated 
Animal W eight (g)
Pre-disease (group 1) 55 32.3 8 31.1
Pre-disease (group 2) 56 34.4 2 33.3
Acute (group 1) 49 30.4 25 30.6
Acute (group 2) 43 33.0 12 32.8
First Remission (group 1) 48 30.4 24 30.1
First Remission (group 2) 50 29.1 17 28.0
Relapse (group 1) 57 32.4 6 33.3
Relapse (group 2) 54 32.2 40 33.3
Second Remission (group 1) 47 31.0 38 30.0
Second Remission (group 2) 51 30.4 31 29.9
Table 5.1: Animal Sample Numbers Analysed: A summary of the animals from 
which the spinal cords were obtained showing the inoculated animals alongside their 
corresponding controls. The left hand side of the table provides information relating 
to the disease phase at which the spinal cord tissue was obtained. The animals have 
been assigned to either group 1 or group 2. Group 1 experiments were conducted 
first and group 2 experiments were used to assess the reproducibility. Spinal cord 
sections were analysed using MALDI MSI alongside their corresponding weight 
match control (un-inoculated).
5.5.2.1 Spinal Cord
The tops of the spinal cords (cervical section), approximately 1cm in length, were 
removed from the rest of the spinal cord using a disposable blade as shown in figure 
5.2. They were then transferred to cryomoulds where they were embedded in 
carboxymethylcellulose (CMC) in order to aid the sectioning process. CMC was 
made to a concentration of lmg/mL in water and forms a liquid gel-like substance. 
The CMC was pre-cooled and poured into the cryomould, the spinal cord was added 
and the cryomould was lowered carefully into liquid nitrogen to ensure that the 
sample did not thaw. This method ensured that the orientation of the tissue could be 
controlled. Sections of 12pm were obtained by cryosectioning (Leica CM1510) the
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spinal cord. These sections were mounted onto an aluminium support and then 
affixed to a MALDI target plate for analysis.
Cryosectioned for MALDI MS 
Analysis
Figure 5.2: Photograph of a Spinal Cord and the Area Taken for Analysis: 1cm
in length from the top of the spinal cord (cervical) was removed from the rest of the 
spinal cord, embedded in CMC and then cryosectioned.
S.5.2.2 M atrix  A pplication
The matrix used was a-CHCA made to a concentration of 5mg/mL in 70% ethanol, 
30% water, containing 0.1 % TFA. The matrix was applied to the tissue surface using 
a Suncollect automated matrix sprayer that operated at 2bar (200kPa) pressure. The 
matrix was in 5 layers; the first layer coated the tissue applying 2pL/min; the second 
layer 3pL/min and the next three layers 5pL/min. This method of matrix application 
is thought to extract the endogenous compounds within the tissue to allow them to 
co-crystallise with the matrix and also allows for a homogenous covering of the 
sample in matrix. This improves on former manual airspraying techniques that relied 
on a skilled operator applying the matrix onto the tissue surface.
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5.5.3 MALDI MS Images
The images presented were obtained from spinal cord sections from the 
cervical/partial thoracic area of 108pm depth. The resolution of each image is 
150pm x 150pm with a laser power of 30% (30pJ). The laser was rastered over the 
tissue section at set increments of 150pm acquiring data for a period of two seconds 
per spot. The mass spectrometer was calibrated prior to image acquisition and the 
data obtained was recalibrated post acquisition with the matrix peaks of a-CHCA to 
ensure the mass accuracy was as precise as possible.
The scale on the right hand side of the images contained within this chapter 
represents the ion intensity; the dark blue colour being the most intense (i.e. 
accounting for more ions) and the lighter blue/white colour accounting for fewer 
ions.
5.6 Haematoxylin and Eosin (H&E) Staining of Spinal Cord Sections
In order to confirm that the diseased animals had inflammatory cell infiltrates in the 
spinal cord, serial sections were collected on glass microscope slides and stained 
with H&E. It was found that the relapse disease stage tissue showed the most 
significant signs of inflammation as shown in figure 5.3.
The sections were fixed using ethanol followed by immersion in graded ethanol 
solutions for 1 minute periods (100%, 90% and 70%). This was followed by 
immersing the sections in 5% Haematoxylin solution for 40 seconds and then the 
sections were rinsed under running tap water to remove the excess haematoxylin 
stain; this was done until the water ran clear. The sections were then immersed in 
eosin for 40 seconds, followed by a 10 second immersion step in water. The sections 
were immersed in graded solutions of ethanol for 1 minute periods (70%, 90%, 
100%). The slides were finally immersed in Xylene for 30 minutes and then 
mounted with coverslips using DPX mounting medium.
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5.7 Results and Discussion
5.7.1 H&E Stained Spinal Cord Sections
Figure 5.3: H&E Stained Spinal Cord: Representative microscope images were 
taken adjacent to the sections taken for MALDI MSI analysis. A: sample 54 x 40 
magnification; B: sample 54 x 100 magnification; C: sample 40 x 100 magnification; 
D: sample 40 x 200 magnification; E: sample 57 x 40 magnification; F: sample 57 x 
100 magnification; G: sample 6  x 100 magnification and H: sample 6  x 200 
magnification. Inflammation was observed most significantly in the samples taken 
from the relapsing animals (samples 6  and 40). The meningeal perivascular cell 
infiltrates are shown with the red arrows. The controls showed no signs of 
inflammation.
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5.7.2 Multivariate Analysis
Principal Component Analysis (PCA) was performed to investigate the major 
differences between the control samples and the diseased samples. It was found that 
the ion at m/z 104.11 was consistently different in the disease stages.
The data was entered into the metabolite database, Metlin [32] where it was found that 
the ion detected at m/z 104.11 could be from choline. Choline is an important 
cellular component of both plant and animal tissue; it can act as a methyl donor in 
metabolic processes, as a precursor for acetylcholine and play a role in lipid 
metabolism. Elevated choline levels in pre-lesional normal-appearing white matter 
in multiple sclerosis have been reported by Tartaglia et al. [241 using proton magnetic 
resonance spectroscopy (MRS). They found that changes in the myelin prior to 
lesion formation, with or without inflammation, can produce elevated 
Choline/Creatine (Cho/Cr) ratios without any related demyelination.
The PCA data presented in this chapter has been normalised against the matrix peak 
at m/z 190.05 and the matrix peaks were excluded from the analysis.
Confirmatory analysis was performed by MS/MS to validate the metabolite search 
shown in figure 5.7.
5.7.3 Investigation of Peak at m/z 104.11
The PCA data presented in sections 5.7.6 and 5.7.7 show that the ion at m/z 104.11 
appears to be the most significant difference between the healthy and the diseased 
tissues. Conventional MALDI MS experiments were conducted to investigate if this 
peak was a matrix related peak. It was found that there was a matrix-related ion at 
m/z 104.10, as shown in figure 5.4c. However, a peak at 104.11 was detected from 
the tissue surface as shown in figure 5.4a and b.
- 1 6 6 -
m/z 104.1078
idd
m/z
542
500
450
400
350
300
250
200
150
100
50
0*1
104.1084
14(1.0649
llL
m/z 104.1084
41
17 ^ -296.0^46
476.9911,1.1..iji UL ■ ^558 4052 704.0002 798.5579j326.5860 ^931.0021
m/z
96.0492 I
m/z 104.1039
I
m/z
Figure 5.4: MALDI-MS Spectra of Relapse Stage Spinal Cord: Example spectra 
for the relapse disease phase: (a) spectrum recorded from sample 6  (inoculated 
mouse); (b) the corresponding control -  sample 57 (un-inoculated mouse); (c) matrix 
blank showing that a peak is present at m/z 104.10
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Figure 5.5: MALDI-MS Spectra and Images to Investigate m/z 104: (a) shows 
the matrix peak present at m/z 104.1045; (b) shows the more intense peak observed 
on the spinal cord section at m/z 104.1080.
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5.7.4 MS/MS Analysis
The observed mass at m/z 104.11 appeared to differ in ion intensity in the diseased 
animals compared with the healthy controls; this was highlighted in the PCA data. 
The use of a chemical matrix can present problems in metabolomic analyses as 
discussed in chapter 4. However, to allocate the observed mass with a potential 
metabolite MS/MS was performed. A matrix peak occurs at m/z 104.10 and 
therefore MS/MS analysis was performed to differentiate between the matrix and 
other possible metabolites.
Figure 5.6: The Chemical Structure of Choline: 
Formula: CsHmNO*
RMM: 104.11
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Figure 5.7: MALDI MS/MS Analysis of m/z 104: Product ion spectra for the
verification of the mass observed at m/z 104.11: (a) the product ion spectrum 
showing the fragmentation pattern of the matrix peak observed at m/z 104.10; (b) the 
product ion spectrum showing the fragmentation pattern observed when choline (m/z 
104.11) standard was ionised off spinal cord tissue; (c) the product ion spectrum 
showing the fragmentation pattern for m/z 104.11 present in spinal cord tissue.
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5.7.5 Assessment of the Matrix Coverage
Matrix coverage is an important aspect of successful MALDI MS analyses. The 
overall aim of the optimal sample preparation procedures is to obtain a homogenous 
coating of matrix across the sample surface. This is generally achieved using 
automated matrix applicators as this allows for the matrix application procedure to be 
consistent and reproducible. The presence of endogenous compounds and salts may 
vary across the surface of biological tissue; therefore image normalisation is 
required. Figure 5.8 shows the coverage of the protonated matrix peak of m/z 
190.05. The reduced signal intensity of the matrix ion on the surface of the spinal 
cord section indicates that endogenous compounds within the tissue are suppressing 
the matrix ion signal at m/z 190.05. To account for this, image data was normalised 
against this matrix peak to account for any slight differences in matrix coverage. The 
left hand side of each image represents the top of the spinal cord.
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Figure 5.8: Assessment of Matrix Coverage at m/z 190.05: The matrix
distribution appears to be relatively homogenous over the tissue surface. However, it 
is apparent that endogenous compounds contained in the tissue are suppressing the 
matrix co-crystallisation process. This can be seen in the image presented by a 
reduction in the matrix signal intensity over the tissue surface. To account for 
differences/unevenness in matrix coverage the data was normalised against the 
matrix peak at m/z 190.05.
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5.7.6 MALDI MSI and PCA Results for Spinal Cord Sections 
(Group 1)
For the PCA analysis and statistical analysis five spectra were randomly selected 
across the spinal cord tissue. The results from the PCA support the image data, 
therefore this was deemed a sufficient dataset for this particular study.
The results presented for the first group of experiments show that the ion detected at 
m/z 104.11, assigned tentatively to choline is significant in the acute, relapse and 
potentially the second remission tissue samples although in the latter group there is 
slight overlap between the control and disease. This observation is supported in the 
images by either increased ion intensity (i.e. 104.11 is more abundant in the tissue 
sample) or decreased ion intensity (i.e. 104.11 is less abundant in the tissue sample) 
and by the statistical comparisons in figure 5.14. The data that was used for the 
PCA was also used to deduce any statistical relevance. It was found that in both the 
acute stage tissue and the relapse tissue the presence of m/z 104.11 was significant.
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Figure 5.9: MALDI MS Images and Multivariate Analysis of Pre-disease Stage 
Samples (Group 1): (a) the distribution of m/z 104.11 in the spinal cord section 
taken from the inoculated mouse (sample 8 ); (b) the corresponding m/z 104.11 
distribution image from the spinal cord tissue obtained from the healthy un­
inoculated control (sample 55); PCA results: (c) There is almost total overlap 
between the diseased and control sample; however, it is clear from the scores plot 
and (d) the corresponding loadings plot that sample 55 (un-inoculated control) 
groups more towards m/z 104.11. Thus the difference between the samples is 
brought about by the compound, potentially choline, at m/z 104.11.
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Figure 5.10: MALDI MS Images and Multivariate Analysis of Acute Stage 
Disease Samples (Group 1): (a) the distribution of m/z 104.11 in the spinal cord 
section taken from the inoculated mouse (sample 25); (b) the corresponding m/z 
104.11 distribution image from the spinal cord tissue obtained from the healthy un­
inoculated control (sample 49); PCA results: (c) the scores plot shows that there is 
grouping of the data between the diseased and healthy samples (d) the corresponding 
loadings plot shows that sample 25 (inoculated control) groups more towards m/z 
104.11.
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5.7.6.3 First Remission Stage Tissue
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Figure 5.11: MALDI MS Images and Multivariate Analysis of First Remission 
Stage Disease Samples (Group 1): (a) the distribution of m/z 104.11 in spinal cord 
section taken from the inoculated mouse (sample 24); (b) the corresponding m/z 
104.11 distribution image from the spinal cord tissue obtained from the healthy un­
inoculated control (sample 48); PCA results: (c) data showing overlap between the 
diseased and corresponding control sample, (d) the corresponding loadings plot
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Figure 5.12: MALDI MS Images and Multivariate Analysis of Relapse Stage 
Disease Samples (Group 1): (a) the distribution of m/z 104.11 in spinal cord
section taken from the inoculated mouse (sample 6 ); (b) the corresponding m/z 
104.11 distribution image from the spinal cord tissue obtained from the healthy un­
inoculated control (sample 57); PCA results: (c) shows significant grouping between 
the diseased and corresponding control sample. The scores plot and the 
corresponding loadings plot (d) show this difference to be brought about by the 
presence of m/z 104.11 as sample 57 groups more towards the m/z 104.11 in the 
loadings plot.
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Figure 5.13: MALDI MS Images and Multivariate Analysis of Second 
Remission Stage Disease Samples (Group 1): (a) the distribution of m/z 104.11 in 
spinal cord section taken from the inoculated mouse (sample 38); (b) the 
corresponding m/z 104.11 distribution image from the spinal cord tissue obtained 
from healthy un-inoculated control (sample 47); PC A results: (c) data showing 
significant grouping between the diseased and corresponding control sample. The 
scores plot and (d) the corresponding loadings plot show this difference to be brought 
about by m/z 104.11 as sample 47 groups more towards the m/z 104.11 in the 
loadings plot.
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5.7.6.6 Statistical Comparisons
A Kolmogorov-Smirnov test revealed that the sample is normally distributed: Z = 
0.147; p>0.05. An independent-samples t test was used to assess the significance of 
differences between disease and matched control sample means for each stage of 
EAE progression.
12
Control
Pre Acute 1st Rem Relap 2nd Rem
Figure 5.14: Group 1 Disease Stage Comparisons: A graph to show the
differences between the diseased samples and the corresponding weight-matched 
controls (Mean ± SEM). The most significant differences in the levels of choline 
detected can be seen at acute and relapse stages of disease. This graph was produced 
using the same five spectra that were used for PCA analysis. (*=P<0.05, **=P<0.01, 
***=P<0.001).
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Disease Stage t statistic Significant?
Pre-disease -0.03 No
Acute 3.12 Yes*
1st rem ission -0.69 No
Relapse -7.86 ye s ***
2nd Remission -2.10 No
Table 5.2: t-test Results for Group 1 Disease Stage Comparisons: Data relates to 
figure 5.14 and corresponding significance (*=P<0.05, **=P<0.01, ***=P<0.001).
The results for the first group of experiments show that the most significant changes 
occur at acute phase and relapse stages of disease; this is supported with significant 
separation between the groups being observed with the PCA analysis and the t-test 
results.
5.7.7 M A LD I M SI and PCA Results for Spinal C ord  Sections 
(G roup 2)
The results presented for group two analysis conflict with the first group of results 
generated in that the pre-disease, acute, relapse and second remission stage samples 
appear to show that there are differences related to the abundance of m/z 104.11 
between the healthy and the diseased samples. However, the statistical analysis 
performed in section 5.7.7 . 6  show only pre-disease, acute and second remission 
samples to be significantly different. After closer inspection of the PCA data for the 
relapse stage it appears that some of the grouping of the datasets shown in the scores 
plot could be due to not only the m/z 104.11 but also by the presence of additional 
masses that appear to be lipids.
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Figure 5.15: MALDI MS Images and Multivariate Analysis of Pre-disease
Stage Samples (Group 2): (a) the distribution of m/z 104.11 in the spinal cord 
section taken from the inoculated mouse (sample 2 ); (b) the corresponding m/z 
104.11 distribution image from the spinal cord tissue obtained from the healthy un­
inoculated control (sample 56); PCA results: (c) there is some overlap between the 
diseased and control sample; however, it is clear from the scores plot and (d) the 
corresponding loadings plot that sample 56 (un-inoculated control) groups more 
towards m/z 104.11.
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Figure 5.16: MALDI MS Images and Multivariate Analysis of Acute Stage 
Disease Samples (Group 2): (a) the distribution of m/z 104.11 in the spinal cord 
section taken from the inoculated mouse (sample 1 2 ); (b) the corresponding m/z
104.11 distribution image from the spinal cord tissue obtained from the healthy un­
inoculated control (sample 43); PCA results: (c) there is some overlap between the 
diseased and control sample; however, it is clear to see from the scores plot and (d) 
the corresponding loadings plot that sample 43 (un-inoculated control) groups more 
towards m/z 104.11.
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Figure 5.17: MALDI MS Images and Multivariate Analysis of First Remission 
Stage Disease Samples (Group 2): (a) the m/z 104.11 distribution in the spinal cord 
section taken from the inoculated mouse (sample 17); (b) the corresponding m/z 
104.11 distribution image from the spinal cord tissue obtained from the healthy un­
inoculated control (sample 50); PCA results: (c) There is some overlap between the 
diseased and control sample; however, it is clear from the scores plot and (d) the 
corresponding loadings plot that sample 50 (un-inoculated control) groups more 
towards m/z 104.11.
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Figure 5.18: MALDI MS Images and Multivariate Analysis of Relapse Stage 
Disease Samples (Group 2): (a) the m/z 104.11 distribution in the spinal cord 
section taken from the inoculated mouse (sample 40); (b) the corresponding m/z
104.11 distribution image from the spinal cord tissue obtained from the healthy un­
inoculated control (sample 54); PCA results: (c) There is significant grouping 
between the diseased and control sample; however, it is clear from the scores plot 
and the corresponding loadings plot (d) that sample 40 (inoculated control) groups 
more towards m/z 104.11.
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Figure 5.19: MALDI MS Images and Multivariate Analysis of Second
Remission Stage Disease Samples (Group 2): (a) the m/z 104.11 distribution in the 
spinal cord section taken from the inoculated mouse (sample 31); (b) the 
corresponding m/z 104.11 distribution image from the spinal cord tissue obtained 
from the healthy un-inoculated control (sample 51); PCA results: (c) there is some 
overlap between the diseased and control sample; however, it is clear from the scores 
plot and (d) the corresponding loadings plot that sample 51 (inoculated control) 
groups more towards the m/z 104.11.
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5.7.7.6 Statistical Comparisons
A Kolmogorov-Smirnov test revealed that the sample is normally distributed: Z = 
0.8346; p>0.05. An independent-samples t-test was used to assess the significance of 
differences between disease and matched control sample means for each stage of 
CREAE progression.
Control
Pre Acute 1st Rem Relap 2nd Rem
Figure 5.20: Group 2 Disease Stage Comparisons: A graph to show the
diffrences between the diseased and control tissue samples. The main differences are 
observed to be at the acute, relapse and second remission stages. (*=P<0.05, 
**=P<0.01, ***=P<0.001).
Disease Stage t statistic Significant?
Pre-disease -2.43 Yes*
Acute -2.39 Yes*
1st rem ission 1.15 No
Relapse 1.64 No
2nd Remission -3.20 Yes*
Table 5.3: t-test Results for Group 2 Disease Stage Comparisons. Data relates to 
figure 5.20 and corresponding significance (*=P<0.05, **=P<0.01, ***=P<0.001).
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Group 2 experiments were undertaken to assess the reproducibility; however, the 
data generated did not support the first group of data. The t-test indicated that pre­
disease, acute and second remission were significant; however, it seems unlikely that 
the predisease samples should differ as there was no sign of inflammation in these 
samples when the histology was undertaken. This would need to be further 
investigated and could potentially be attributed to matrix interference. However, 
lesions where there are changes in the myelin without any evidence of inflammation 
have been reported [33]. Thus these apparent changes in choline may be a marker for 
this early type of lesion.
As the controls indicate that there are natural fluctuations in choline levels between 
the animals, biological variability between different animals is also significant and 
has made the interpretation of data from this small preliminary study tentative at 
present.
5.7.8 Com bined Analysis (Group 1 & Group 2)
A Kolmogorov-Smirnov test on the combined data revealed that the sample is 
normally distributed: Z = 0.147; p>0.05. An independent-samples t test was used to 
assess the significance of differences between disease and matched control sample 
means for each stage of EAE progression with the pooled data from groups 1 and 2.
The pooling of the data from both group 1 and group 2 experiments shows that the 
abundance of the m/z 104.11 is only significant in the second remission samples.
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Control
Pre Acute 1st Rem Relap 2nd Rem n=2
Figure 5.21: Combined Disease Stage Comparisons: A graph to show the
diffrences between the diseased and control tissue samples where the data from 
groups 1 and 2 are pooled. The only significant difference was observed at the 
second remission stage. Any previous significance from the individual groups was 
lost (*=P<0.05, **=P<0.01, ***=P<0.001).
Disease Stage t statistic Significant?
Pre-disease -0.60 No
Acute 0.08 No
1st rem ission 0.62 No
Relapse -0.36 No
2nd Remission -2.99 Yes**
Table 5.4: T-test Results for Combined Disease Stage Comparisons. Data relates 
to figure 5.21 and corresponding significance (*=P<0.05, **=P<0.01, ***=P<0.001).
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In section 5.7.6 and 5.7.7 the results have been presented separately (i.e. the data has 
not been pooled for all the experiments) as the two sets of data generated do not 
support each other. By combining the data from experimental groups 1 and 2, 
significance between disease stage tissue and corresponding controls seen in the 
individual groups (as assessed by t-test statistic) was lost. Averaging the observed 
changes created greater variability within the different stages. This meant that 
differences were no longer statistically significant, as seen previously with acute, 
relapse (groupl) and predisease, acute (group 2) disease stages (see figures 5.14, 
5.20 and 5.21).
This highlights the importance of reproducibility between samples and the 
consideration of individual differences within animal populations, and emphasises 
the need for larger 'n' numbers when stating differences between biological samples. 
The use of larger 'n' numbers reduces the possibility of drawing false conclusions 
from experimental observations. The significance of biological variability has been 
acknowledged by Lay et al. stating that even in in-bred mice there is often significant 
biological variability [34].
Within this preliminary data, however, the second remission disease stage of CREAE 
retained statistical significance for the normalised choline intensity, as compared 
with healthy control tissue, when the groups were combined. The lower level of 
choline in this stage of the disease may be of potential biological and clinical 
relevance as lower choline levels have previously been reported [26].
5.9 Conclusion
The use of MALDI MSI generated some interesting results; however, the presence of 
interfering matrix peaks in the spectral region of interest proved to be a problem. 
The tandem mass spectrometric (MS/MS) analysis confirmed that it is possible that 
the peak at m/z 104.11 could be attributed to the presence of choline within the tissue 
section. However, the mass of the matrix peak and the choline mass are very close 
and therefore, although the images have been generated for m/z 104.11 and 
normalised against the matrix peak at m/z 190.05, any fluctuations in the matrix ion
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also at m/z 104 could potentially produce a misleading image. This could be further 
investigated by acquiring images in MS/MS mode i.e.; this preliminary non-targeted 
study could be further investigated using a targeted approach.
The sample preparation procedure, with a particular emphasis on the embedding of 
the tissue prior to cryosectioning, may also need to be re-evaluated as a few of the 
images appear not to be as well defined as other images generated. This could be 
due to the transfer of choline, a water soluble compound to the CMC, as the CMC 
was prepared in water. This would need to be further investigated. However, a more 
likely explanantion is the possible interference from the matrix peak as the imaging 
software only permits images to be accurate to two decimal places. Therefore any 
fluctuations in the measured mass of the matrix peak at m/z 104.10 could produce the 
ill-defined edges observed around the edge of the spinal cord.
Another point of discussion is whether the choline detected and confirmed by 
MS/MS experiments is free choline or a fragment ion arising from choline- 
containing phospholipids by the laser energy settings used for these experiments. 
Therefore, the data is very preliminary for the reasons previously stated and further 
experimentation would be required in order to confidently reach any conclusions 
from this study.
The preliminary data presented shows that MALDI MSI can be used for the imaging 
of spinal cord sections. The results of the PCA show that there are other masses that 
appear to be different in the inoculated and un-inoculated. These masses could be 
further investigated in order to establish the compound identification and to ensure 
that there is no interfering matrix peaks in the spectral region of interest.
Further experiments could be performed on the rest of the spinal cord; this could 
establish if there are differences in metabolite levels down the length of the spinal 
cord. This would be particularly difficult to achieve in the diseased animals as the 
spinal cord is very weak towards the bottom and often falls to pieces prior to snap 
freezing. It would therefore be very difficult to cryosection the spinal cord samples 
and maintain the same orientation between the controls and the diseased animals. 
Experiments could also be performed on the brain tissue of the same animals to
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establish if the observed metabolites in the spinal cord correspond with those that are 
present in the brain.
A proteomics strategy could also be used to complement the results obtained with the 
non-targeted metabolomics to assess the distribution of small molecules in areas of 
demyelination. This could be achieved by performing a tryptic digest on the spinal 
cord section prior to mass spectrometric analysis as the proteins have masses of 
approximately 30kDa [351 and the cytokines that are associated with inflammation 
have masses around 20kDa t36].
The results from this preliminary study demonstrate that MALDI MS is a suitable 
technique to directly analyse tissue samples. Due to time constraints, in this 
preliminary study the combined data of n=2 is not sufficient enough to make any 
significant biological conclusions and the analysis of many more samples is required.
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Chapter 6
Conclusion and Suggestions for Future 
Work
6.0 Conclusion and Suggestions for Future Work
The work presented in this thesis demonstrates the versatility of MALDI MSI for a 
range of different samples. Methodology has been developed for the analysis of 
pharmaceutical compounds (Chapters 2 and 3) and for the application of MALDI 
MSI as a potentially new technique for metabolomic studies (Chapters 4 and 5). The 
quality of the data obtained from MALDI MS is dependent on many factors; the 
most influential of which are related to the type of sample to be analysed, for 
example the type of tissue to be analysed and the sample preparation procedures 
employed prior to the analysis.
The analysis of anti-asthmatic drugs in lung tissue proved to be quite a challenging 
experiment due to the ion suppression brought about from the endogenous 
compounds contained within this type of tissue such, for example relatively high salt 
concentrations. Also, the type of compound to be analysed was a major factor in the 
overall success of an experiment as some compounds ionise more readily than 
others; this was observed with Fluticasone Propionate and GSK256066B. Drug 
distribution studies can provide valuable information relating to the overall drug 
efficiency, for example it has been reported in the literature that Fluticasone 
Propionate has been observed to accumulate in the lung undissolved; this is clearly 
an issue in terms of how effective the drug is in relieving the symptoms of the 
patient. As there were problems with the co-crystallisation process with the organic 
matrix a-CHCA on the surface of the lung tissue due to the presence of endogenous 
compounds such as high salt concentrations, a blotting approach was used as an 
alternative in an attempt to analyse the drugs that couldn't be detected directly. 
Particle suspension matrices were also investigated as an alternative to the more 
conventional organic acid matrices as they work via a thermal effect in contrast to 
the co-crystallisation that occurs between organic acid matrices and the sample. 
Future studies in this area could involve derivatisation of the anti-asthmatic 
compounds to make them more easily ionisable, this could be achieved through the 
matrix application by modifying the matrix, thus derivatising the compound of 
interest in situ.
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Another type of pharmaceutical analysis was performed in chapter 3 whereby tablet 
pharmaceutical formulations were analysed in an attempt to obtain information 
relating to the homogeneity of the active drug throughout the excipients contained 
within tablet formulations. This can provide valuable information that relates back to 
the manufacture of the tablet, this is especially important in slow release 
formulations. The importance of the sample preparation procedure is highlighted 
with regard to the sample morphology. It was found that tablets with a curved 
surface produced poor quality images due to a potential laser focussing problem 
resulting in the doughnut effect that can be clearly seen in the data. Future 
experiments could be undertaken to investigate the optimum laser positioning for 
such studies.
In Chapters 4 and 5 MALDI MSI has been assessed for its contribution to existing 
techniques that are used to study metabolomics. The concept of metabolomics arose 
primarily from the analysis of plant tissue and is gaining prominence in the area of 
biomarker discovery. The requirements for high throughput techniques that can 
detect metabolites in parallel make MALDI MSI a logical consideration to provide 
complementary information to existing techniques such as LC-MS. The work 
presented in chapter 4 details a metabolomics approach to study the metabolites 
contained within wheat grains. Aspects of the sample preparation procedure in 
relation to preserving the metabolic status of the tissue section have been discussed. 
A major problem with this type of analysis was not surprisingly the interference of 
matrix peaks in the spectral regions of interest and the suppression of the metabolites 
due to the presence of intense matrix peaks. However, the matrix peaks can also act 
as internal calibrants that are useful for the recalibration of data for accurate mass 
measurement. A range of matrices were tested in an attempt to increase the 
achievable sensitivity. F20TPP matrix peaks occur at around m/z 800 - m/z 1000; 
however, this matrix did not appear to ionise the endogenous metabolites contained 
within the section as well as a-CHCA and appeared to suppress the ionisation of the 
sugars that were observed using a-CHCA. The use of gold and silver nanoparticles 
was also investigated but did not yield good results. This is probably because they do 
not co-crystallise with the sample and thus extract the metabolites; this is also true of 
the particle suspension matrices that have also been investigated. As consistency
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with sample preparation is a critical factor in achieving high quality reproducible 
data, a number of commercially available devices have been developed in order to 
control the variability in the matrix application procedure, however their use is 
generally not suited to the use of particle suspension matrices and nanoparticles due 
to problems encountered with devices that use a small diameter needle to apply the 
matrix as these matrices can block the needle.
The IR LDI MS data obtained from the collaboration with the University of Munster 
provided a matrix free option to obtain data that was purely sample related. This is 
because the IR laser emits at a different wavelength to UV lasers such as Nd: YAG 
and Nitrogen lasers that is also the wavelength at which water molecules absorb, thus 
residual water contained within samples acts as an endogenous matrix promoting the 
ionisation of molecules from the sample surface. The sugar ions dominate the 
spectra and this could have potentially suppressed the ionisation of the less abundant 
smaller mass metabolites. However, a compromise had to be reached between the 
preparation of the plant tissue and the associated instrumental parameters; the use of 
freeze dried tissue did not produce good results but this isn't surprising considering 
that the freeze drying process removes the residual water from the tissue. 
Rehydrating experiments could be used to help combat this problem, however this 
would result in the delocalisation of the metabolites and results generated from 
profiling/imaging experiments would potentially be misleading.
The establishment of methodology for plant material in Chapter 4 led into the animal 
work described in Chapter 5 where MALDI MSI was used to investigate the animal 
model of multiple sclerosis (chronic relapsing experimental autoimmune 
encephalomyelitis) in an attempt to discriminate at the metabolomics level between 
healthy controls and the corresponding diseased tissue at five different stages of the 
disease progression. The images obtained correlated with the multivariate analysis 
obtained by performing principal component analysis on the data generated. The 
results obtained showed that potentially choline levels can fluctuate from animal to 
animal as can be observed from the control samples. However, at the specified 
stages in the disease process it was found that the levels of choline detected were 
different to those of the control samples. The data presented in this chapter is very
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preliminary and to draw any significant biological conclusions from the data 
obtained more samples would need to be analysed.
Metabolomics experiments generate large volumes of data and it is not feasible to 
conduct MS/MS experiments for every mass that is detected at present using MALDI 
MSI, especially in non-targeted metabolomics experiments. The development of 
appropriate software for high throughput metabolomics using MALDI is crucial to 
the future analyses. Software is currently available from Waters (MSE) for LC-MS 
analyses that acquire both MS and MS/MS data simultaneously; a similar approach 
would be useful for MALDI analyses as this would immediately eliminate the matrix 
peaks observed from the endogenous compounds contained within the sample of 
interest and help in the identification of unknown masses. There is a lack of 
complete databases for metabolomic studies, the development of metabolite 
searching software would be beneficial as many databases can contain metabolites 
that are found in many organisms and they don't always take into account the adducts 
that are commonly formed in MALDI analyses, therefore in some instances the data 
has to be converted into the corresponding neutral masses.
Mass spectrometry is becoming increasingly popular due to its expanding role in the 
biosciences. It is an unparalled technique in many ways owing to its excellent 
sensitivity, specificity, speed, it can be applied to many classes of compound and it 
can be coupled to separation techniques if required. With advancements in mass 
spectrometers and data processing applications, the role of mass spectrometry is ever 
increasing and will be adopted furthermore in the advancement of biomedical 
research.
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